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Orthopedic and oro-maxillofacial implants have revolutionized treatment o f bone 
diseases and fractures. Currently available metallic implants have been in clinical use for 
more than 40 years and have proved medically efficacious. However, several drawbacks 
remain, such as excessive stiffness, accumulation o f  metal ions in surrounding tissue, 
growth restriction, required removal/revision surgery, inability to carry drugs, and 
susceptibility to infection. The need for additional revision surgery increases financial 
costs and prolongs recovery time for patients. These metallic implants are bulk 
manufactured and often do not meet patient’s requirements. A surgeon must machine 
(cut, weld, trim or drill holes) them in order to best suit the patient specifications.
Over the past few decades, attempts have been made to replace these metallic 
implants with suitable biodegradable materials to prevent secondary/revision surgery. 
Recent advances in biomaterials have shown multiple uses for lactic acid polymers in 
bone implant technology. However, a targeted/localized drug delivery system needs to be 
incorporated in these polymers, and they need to be customized to treat orthopedic 
implant-related infections and other bone diseases such as osteomyelitis, osteosarcoma 
and osteoporosis. Rapid Prototyping (RP) using additive manufacturing (AM) or 3D 
printing could allow customization o f constructs for personalized medicine. The goal o f 
this study was to engineer customizable and biodegradable implant materials that can 
elute bioactive compounds for personalized medicine and targeted drug delivery.
Post-operative infections are the most common complications following dental, 
orthopedic and bone implant surgeries. Preventing post-surgical infections is therefore a 
critical need that current polymethylmethacrylate (PMMA) bone cements fail to address. 
Calcium Phosphate Cements (CPCs) are unique in their ability to crystallize calcium and 
phosphate salts into hydroxyapatite (HA) and hence is naturally osteoconductive. Due to 
its low mechanical strength, its use in implant fixation and bone repair is limited to non­
load-bearing applications. Novel CPCs were formulated and were doped with drug 
loaded Halloysite Nanotubes (HNTs) to enhance their mechanical and anti-infective 
properties.
In this study we also explored the use o f  customized biopolymer filaments and 3D 
printing technology to treat bone diseases such as osteomyelitis, osteosarcoma, and 
osteoporosis. Biopolymer filaments were successfully loaded with antibiotics, 
chemotherapeutics and hormones (female sex hormones). Using a Fused Deposition 
Modeling (FDM)-based 3D printer, these customized filaments were fabricating into 3D 
scaffolds. Constructs with variable mechanical strengths and porosities were successfully 
designed and 3D printed. Scanning electron microscopy was used to study the surface 
architecture o f the scaffolds. Compression and flexural testing was conducted for testing 
the mechanical strength o f  the constructs. Bacterial and suitable cell culture studies were 
applied to test bioactivity o f the constructs. From above experiments, this study showed 
that 3D printing technology can be used to fabricate bioactive biopolymers for 
personalized medicine and localized drug delivery.
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CHAPTER 1
INTRODUCTION
1.1 Bone Implant Technology
Bone fractures are the most common injuries resulting from accidents, age, and 
bone-related diseases. As bone is a metabolically active tissue, it undergoes continuous 
interplay between the bone-resorbing osteoclast and the bone-forming osteoblast cells 
throughout life, enabling it to repair small defects [1], However, bone tissue cannot repair 
large bone defects and severe fractures. The choice o f treatment modality depends on the 
severity o f the fracture. When a bone cannot regenerate itself, bone grafts are implanted. 
Bone grafting is defined as “a surgical procedure that places new bone or a replacement 
material into spaces between or around broken bone (fractures) or in holes in bone 
(defects) to aid in healing” [2]. Bone implants are also used to treat bone disorders such 
as osteomyelitis and osteosarcoma, where the infected parts o f the bone are resected and 
filled with drug eluting bone implants.
Autograft, allograft, and synthetic materials are the three material choices used in 
modem grafting procedures. A graft made from a patient’s own bone (usually hip bones 
or ribs) is called an autograft. To obtain a piece o f  bone for an autograft, the patient is 
subjected to surgery under general anesthesia, and the bone is removed, typically from 
the iliac crest. An incision is made, the bone is removed, and the wound site is closed. An
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allograft uses bone taken from a cadaver or, less frequently a living donor, and frozen and 
stored [2, 3], Chemical compounds, such as calcium phosphate (CP), PMMA and 
polyether ether ketone (PEEK) are used as synthetic materials to fill the fractured spaces
[4].
An ideal bone graft should have the bioactive properties o f osteogenesis (the 
formation o f new bone), osteoinduction (the chemical process o f  inducing a conversion 
o f patient’s osteoprogenitor cells into osteoblasts), and osteoconduction (providing a 
scaffold for cells to form new bone) [3],
1.2 Need for Improved Implant Technology
A surgeon places the graft by making an incision in the skin over the bone defect 
and shapes the replacement material into the graft site. Pins, plates, or screws are used to 
position the graft, and the incision is stitched closed. The supply o f allografts and 
xenografts is limited. These materials can be rejected by the host’s immune system, can 
transmit diseases, and pose a high risk o f contamination.
Currently available metallic implants have been used clinically for more than 40 
years and have been medically efficacious. However, in spite o f their success, they are 
subject to several drawbacks, such as excessive stiffness, accumulation o f metal ions in 
the surrounding tissue, growth restriction, required removal/revision surgery, inability to 
carry drugs, and susceptibility to infection [5, 6, 7], Moreover, additional revision surgery 
results in increased financial costs and prolonged recovery time for patients.
The search for an alternative to replace these metal implants has been largely 
focused on bioabsorbable materials. Many biopolymers such as poly-lactic acid and poly 
glycolic acid have showed multiple o f uses in the implant technology. However, these
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polym er’s properties such as mechanical strength and time o f degradation need to be 
customized according to the site o f implantation [6], Biopolymers when used as implants 
will not necessitate a secondary surgery and they can also be engineered to degrade at the 
rate o f new tissue formation, transforming the load gradually from implant to the newly 
formed tissue. In addition, they are widely available in different forms (solids, gel, fibers) 
and can be easily molded into different shapes and compositions. Therefore, there is a 
need to replace the traditional metallic implants with biodegradable materials.
Contamination during the medical process can be caused by many factors, such as 
biomaterial chemistry o f the implant material, their surface physical properties, design o f 
the medical device, anatomical site o f implantation, the extension o f surgical invasion, 
and the time o f application [8], In orthopedic surgeries, use o f biomaterials involves a 
high risk o f developing infections [9]. Because bacteria can attach to these biomaterials 
and develop resistance by forming biofilms, treating these infections systemically is 
difficult and localized treatment was proven efficient [10]. High-infection rate also 
imposes a high financial cost [11]. It is therefore important to prevent infection during 
bone implantation.
In medical conditions such as osteomyelitis, where bone is infected by 
microorganisms, the infected parts o f the bone are resected and filled with antibiotic 
eluting implants. Bone cements added with anti-infective agents molded in the shape o f 
beads or pellets are commonly used for this purpose [12]. Similarly, in osteosarcoma, 
cancerous bone is resected and voids are filled with chemotherapeutic eluting implant 
materials [13]. Commercially available Poly Methyl Methacrylate (PMMA) bone 
cements have good mechanical properties, but they are not biodegradable. They cause
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cytotoxicity to the surrounding tissues due to the methyl methacrylate monomer release. 
So replacement o f the currently available bone implant material with biodegradable or 
bioresorbable implants would be beneficial.
Most bone cements currently used undergo a chemical reaction within the mixture 
and form micro pores o f different sizes. These pores can act as a starting point o f  cracks 
and cause premature failure o f the cement. To avoid this pore formation, cement can be 
mixed under vacuum conditions. Unfortunately, when cement is mixed under vacuum, it 
leads to reduction in volume during polymerization, causing high shrinkage and worse 
adhesion when compared to non-vacuum mixed cement [9],
Several approaches have been used to fabricate anti-infective bone cement. 
Different antimicrobial agents have been used, as well as different ways to bind these 
agents within the bone-cement matrix. Typically, drugs are dry mixed with the bone 
cement and administered into the body. However, the addition o f antibiotics reduces 
mechanical properties in the bone cement. Furthermore, the release o f the antibiotic is 
short-lived and results in less than maximal antibiotic release [14].
The use o f nanoparticle technology as a drug delivery system is a well established 
strategy for enhancing the bioavailability, allowing targeted drug delivery and improved 
therapeutic efficacy. Currently, many nanoparticles are under investigation for treatment 
o f diseases, more specifically for chemotherapeutic and antibiotic drug delivery. Due to 
unique features, such as large surface to mass ratio, ability to load a vast variety o f 
compounds and biocompatibility, nanoparticles such as Carbon Nanotubes (CNT) and 
Halloysite Nanotubes (HNT) are widely used for medical purposes. Gomol et al. replaced 
micro-particles (usually barium sulfate or zirconium oxide) with nanoparticles on
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commercially available PMMA bone cement and found a 41% increase in tensile strain- 
to-failure and a 70% increase in tensile work-of-fracture. They attributed the increase in 
mechanical properties to crack-tip blunting. It is phenomenon where a propagating crack 
is deflected or stopped when a solid particle obstructs its path [ 15].
Currently available metallic implants and therapeutic drugs are bulk manufactured 
and often do not meet the patient’s requirements many times. A surgeon needs to modify 
them (cut, weld, trim, or drill holes for implants and change dosages for drugs) to suit the 
patient’s specifications. Every individual has unique physiology and reacts differently to 
drugs and therapies. Generic medicines do not account for these individual differences. 
Personalized medicine can modify the methods o f therapies and drug delivery to best suit 
the individual. This personalization may help reduce the failure o f treatments and 
improve the functionality o f the tissue. Major advances in biomedical engineering have 
led to new patient’s specific technologies which treat diseases with controlled drug 
delivery and/or replace wounded tissue with biocompatible materials. The 3D printing 
using FDM is one o f them. FDM printing’s high speed, accuracy, affordability, and 
feasibility have led to its increased use in medicine and biotechnology. This technology is 
used in printing prosthesis, human tissues, medical devices, and surgical implants for 
dental and orthopedic applications.
1.3 Objectives
The objective o f  all three projects is to design customizable and biodegradable 
materials that are cytocompatible and can elute bioactive compounds such as antibiotics, 
chemotherapeutics and hormones. The following objectives will be the core focus o f this 
research:
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1. To formulate novel calcium phosphate cements (CPC) with enhanced mechanical 
properties and sustained anti-infective drug release profiles using doped HNTs.
2. To engineer novel methods for fabricating customized anti-infective and 
chemotherapeutic implant materials using biodegradable polymers.
3. To design bioactive polymers enhanced with hormones for personalized medicine 
and hormone replacement therapy.
1.3.1 CPCs Doped with HNTs
CPCs are well known for their osteoinductive and osteoconductive nature, but 
their usage is limited to non-load bearing regions because they have poor mechanical 
properties. Whereas commercially available PMMA bone cements have good mechanical 
strength, they are non-degradable and do not have osteoinductive properties. Moreover, 
their cytotoxicity, caused by the release o f  MM A monomer, and their excessive stiffness 
are undesirable qualities. A crucial need exists to increase the mechanical properties o f 
CPCs. Novel calcium phosphate bone cements are formulated with various combinations 
o f calcium phosphate salts mixing with different aqueous solutions. Natural polymers 
will be added to these combinations to achieve anti-washout properties and increase the 
mechanical strength. They will be allowed to set at ambient temperatures and checked for 
their anti-washout properties. HNTs will be used to increase the mechanical properties 
and also as a drug delivery system.
Change in mechanical properties will be evaluated by compression and flexural 
testing. Surface modifications due to the addition o f  HNTs will be studied using SEM. 
Antibiotic drugs will be loaded in HNTs using vacuum loading techniques and drug 
elution studies will be done to compare anti-infective compound release over time.
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Cytocompatibility o f  these formulated cements will be checked by conducting XTT assay 
on osteoblast cells cultured along with the CPC scaffolds. Bacterial testing using E. coli 
will be performed to check the antibacterial activity.
1-3.2 3D Printing Antibiotic and Chemotherapeutic Constructs
The objective o f  this research is to develop a novel method o f 3D printing 
customized implants using biodegradable materials doped with drugs such as antibiotics 
and chemotherapeutics. Filaments used in a 3D printer will be customized accordingly in 
order to achieve this objective. ExtrusionBot filament extruder will be used to extrude 
bioplastics doped with drugs. These customized extruded filaments will be used in 
MakerBot 3D printer for printing constructs. The goal will also focus on the capability to 
customize the 3D printing parameters in order to match the modified materials.
Thermoplastics are heated for extrusion and printing processes, thermal 
degradation o f  bioactive compounds doped in them may occur. So to test their activity 
bacterial cultures for antibiotic constructs and osteosarcoma cultures for 
chemotherapeutic constructs will be done. Images o f the extruded filaments and printed 
constructs will be taken to study the surface morphology. Compression and flexural 
strengths o f the constructs with and without drugs are compared in order to study the 
effect o f drug doping on the mechanical properties.
In most o f the bone diseases and disorders, the surgeon resects the infected bone 
and fills the resected area with drug eluting implants. Using patient’s data such as X-ray 
or CT scan, defective parts can be processed, 3D printed, and used as implant material.
To test the proof o f principle, defects will be made on the cow femur bone and scanned
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using a 3D scanner. These scanned files will be processed, imported as STLs and will be 
printed with the customized filaments.
1.3.3 3D Printing Hormones
The objective o f this study is to 3D print customizable implant materials which 
can elute hormones for personalized medicine and targeted drug delivery. In this part o f 
the research, hormones (female reproductive hormones) will be coated on to the 
biodegradable thermoplastic materials and filaments o f the required dimensions will be 
extruded. These extruded filaments will be 3D printed and the scaffolds will undergo a 
series o f tests. For surface morphology, SEM will be used; for drug elution profiles, 
spectroscopy will be used, and for testing the bioactivity o f the scaffolds, cell culture 
using estrogen reporter stable cell line will be used.
1.4 Organization of Dissertation
This dissertation is comprised o f six chapters. Chapter 1 is a brief introduction o f 
bone implant technology and its problems, the need for improving the implant 
technology, and the objectives o f this research. Chapter 2 is a detailed review o f bone 
biology, bone diseases and their current treatment modalities. It also focuses on 3D 
printing technology and its applications in the medical field. Chapter 3 focuses on HNTs 
as a potential additive material for enhancing the mechanical properties o f CPCs and also 
as drug delivery system. Chapter 4 covers the novel 3D printing techniques that involves 
manufacturing o f customized biodegradable implants that can elute anti-infective and 
chemotherapeutic drugs and tests for their bioactivity. Chapter 5 investigates 3D printing 
o f hormone eluting implantable materials and their tests for bioactivity. Chapter 6 draws 




The bone is a skeletal connective tissue which provides a structural framework for 
the body. It is a dynamic and highly vascularized tissue that undergoes remodeling, a 
process involving local resorption and formation o f  bone, throughout the lifetime o f an 
individual [16]. It also serves as a mineral reservoir, protects internal organs, creates 
motion by opposing muscular contractions, and is a site o f hematopoiesis. It is made up 
o f both organic and inorganic matter. Bone, like most biological tissues, is hierarchically 
structured to provide the maximum strength with a minimum of material [ 17], In order to 
expedite a full characterization o f the bone, each separate constituent o f the bone that 
contributes to the whole system must be evaluated.
2.1.1 Types o f  Bone
Based on the different proportions o f osseous tissue, bone is classified into 
compact (cortical) and spongy (cancellous). Compact bone is dense, smooth, and 
homogeneous. It also stores calcium and has 70-80% of its matrix calcified [18],
Compact bone is composed o f many cylindrical shaped units called osteons, or haversian 
canals. This type o f bone is abundant in the diaphysis region o f long bones and plays a 
mechanical and protective role [18, 19].
9
10
On the other hand, spongy bone does not contain osteons. It has needle-like bony 
structures with an irregular lattice o f thin columns and plates called trabeculae [20], This 
type o f  osseous tissue has low density and strength but has a high surface area and forms 
the inner cavity o f the epiphyses called bone marrow [19, 21, 22], Bone formation and 
deposition depend upon the mechanical stress applied to them [16, 22], In a study 
conducted by Rubin and Lanyon, functionally isolated avian bone showed an increased 
bone deposition on an application o f rigid-external load and a substantial remodeling on 
removal o f it [23, 24],
2.1.2 Bone Cells
Osteogenic cells, osteoblasts, osteoclasts and osteocytes are the four different 
types o f cells present in the bone. Osteogenic cells are stem cells that undergo mitosis and 
develop into osteoblasts. These are also called osteoprogenitor cells and are present on all 
non-resorptive bone surfaces. They form the deep innermost layers o f the periosteum and 
endosteum.
Osteoblasts are single-nucleated, cuboidal shaped cells that secrete extracellular 
matrix. They also secrete many non-collagenous proteins, such as osteocalcin and 
osteopontin that initiate bone mineralization and maintain calcium homeostasis [25]. The 
lifespan o f  osteoblasts is about eight weeks in humans. These cells are anchorage- 
dependent and rely on extensive cell-matrix and cell-cell contacts to maintain its cellular 
functions. Some osteoblasts get trapped in their own calcified matrix and change their 
phenotype to develop into osteocytes [22].
Osteoclasts are macrophages and are derived from hematopoietic stem cells.
These highly migratory, multinucleated and polarized cells carry lysosomal enzymes. The
11
most intriguing feature o f  osteoclasts is the presence o f apical membrane which can form 
a tight seal with the calcified matrix. An activated osteoclast can resorb 20,000 pm3 o f 
bone minerals per day [22],
Osteocytes are smaller in size than osteoblasts, contain fewer organelles and have 
a high nucleus-to-cytoplasm ratio [22]. They have a high number o f filopodia or 
cytoplasmic extensions interconnecting other osteocytes. These help in the exchange of 
nutrients and waste [18],
2.1.3 Extracellular Matrix (ECM)
Bone extracellular matrix consists o f both organic and inorganic compounds. 
Organic matrix forms 30% o f the complete bone. It contains proteoglycans, 
glycosaminoglycans, osteonectin (anchors bone minerals to collagen) and osteocalcin (a 
calcium binding protein). During the process o f mineralization, glycoproteins, such as 
osteopontin and osteonectin are expressed more and hence serve as the markers for the 
matrix mineralization. Bone has collagen fibers dispersed all over the matrix, providing 
strength and resilience. The inorganic matrix is primarily composed o f mineral salts with 
almost 70% being apatites o f calcium and phosphate. This mineral crystal form, called 
hydroxyapatite, precipitates around collagen fibers o f  osteoids and makes the bone hard, 
resistant to crushing [19].
2.2 Osteosarcoma
Osteosarcomas are the most common primary malignancy o f connective tissue, 
with approximately 900 cases reported every year in the United States [26]. The etiology 
o f this disease remains unknown. Although, several risk factors such as age, gender, use 
o f tobacco and alcohol increase the incidence o f osteosarcoma. People with inherited
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genetic conditions such as retinoblastoma, Li-Fraumeni syndrome, bloom and wemer 
syndrome have an increased risk o f developing this disease [26, 27]. The incidence o f 
osteosarcoma has a bimodal age distribution, having the first peak during adolescence 
and the second peak in the seventh and eighth decade o f  life [27, 28],
The most common primary sites o f osteosarcoma are usually the distal femur and 
the proximal tibia (around knee joints). Pain and swelling in the affected area are the 
common symptoms o f this disease. Pain may become worse, especially during physical 
activity or at night. Several weeks after the pain starts, lumps may be formed at the 
affected site and bones become fragile and vulnerable to fractures. Accurate diagnosis is 
an essential prerequisite for treating the osteosarcoma. Imaging and histological 
confirmation are the two current techniques used for diagnosis. An MRI o f the entire 
bone in which the primary tumor is located, is the first diagnosis test that an 
osteosarcoma patient receives. A Computer Tomography (CT) scan o f the chest will be 
performed to detect any lung metastases. Bone scintigraphy using technetium (commonly 
called as bone scan) o f  the whole body is employed to check any distant spread o f the 
disease and a biopsy o f the tumor is done finally to characterize the type and stage o f the 
tumor [26, 29, 30].
For a successful treatment o f  osteosarcoma, both surgery and chemotherapy are 
necessary. Chemotherapy is administered as neoadjuvant (preoperative) and adjuvant 
(post operative) therapies. Neoadjuvant therapy is used to measure the chemo- 
responsiveness o f  the tumor, attempt to shrink the tumor and avoid extensive surgical 
procedures. This therapy is administered for a period o f  8-10 weeks before the surgery 
[31]. Following the surgery, adjuvant therapy is administered for 12-29 weeks [32], High
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doses o f drugs methotrexate, doxorubicin, cisplatin and ifosfamide are used in both 
phases. Chemotherapy on its own cannot eradicate primary cancer. Therefore, surgical 
treatment is necessary. Amputational and limb-salvage surgeries are the two most 
common, currently performed surgical strategies for osteosarcoma. Due to the recent 
advances in imaging techniques and novel drug delivery systems, approximately 80% of 
osteosarcoma surgeries are performed by limb-salvage surgery [30]. Reconstructions in 
these surgeries are possible with orthopedic implants such as rods, plates, screws, bone 
cements, and other osteoarticular grafts. Amputational surgeries are conducted only in 
severe cases.
Recurrence rate for cancers are generally high. A total o f 30-40% o f patients 
suffer localized osteosarcoma recurrence [33]. For this reason, novel surgical implants 
with drug-eluting capabilities became the focus o f  several studies [34],
2.3 Osteomyelitis
Osteomyelitis is one o f the devastating infectious disease o f the bone, and it 
remains a challenge to the physicians in both diagnosis and treatment [35]. Bones can be 
infected in many ways; infection may spread to the bone from another part o f the body 
through the blood stream, fracture and/or open wound can expose the bone, and 
peripheral vascular diseases or bacteremia can occur. Bones o f  the lower extremity (foot 
and ankle) tends to be more susceptible to infections due to thin soft tissue layers, boney 
prominences, and poor vascular supply. Certain chronic conditions such as diabetes, 
sickle cell anemia and hemodialysis increase the risk o f osteomyelitis [36]. The annual 
incidence o f osteomyelitis is about 54.6 per 100,000 individuals, as per the statistics
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conducted in 2012 [37]. The risk o f  foot ulceration is high in diabetic patients, and these 
ulcerations are often complicated by osteomyelitis [38, 39, 40],
Bone infections begin with adhesion o f bacteria (or any other infectious 
organism) to the bone matrix. The attached organism causes inflammatory responses 
leading to bone necrosis. In addition, inflammatory factors such as IL-1 and TNF trigger 
the osteoclast activity, causing demineralization o f  bone [41], Osteomyelitis is classified 
as acute or chronic, based on the duration o f infection. Acute myelitis occurs over a 
period o f a few days to weeks and has symptoms o f localized pain, edema and redness at 
the site o f  infection. Chronic myelitis is a prolonged recurrence o f  an acute case and is 
characterized by ischemia and bone necrosis [42], Most o f the osteomyelitis is 
polymicrobial in nature. Microbes such as Staphylococcus aureus, Escherichia coli and 
Pseudomonas aeruginosa are the most robust. Staphylococcus aureus is the most 
common causative microorganism for osteomyelitis [43].
The success o f these microbes is due to their ability to form biofilms which 
inhibits wound healing process and increases the susceptibility o f  the host to 
osteomyelitis. In addition, these biofilms are tough and do not allow easy penetration o f 
antibiotics into their matrix, making them more resistant to anti-infective agents [35]. 
Thus, a method is needed to treat the biofilms in the wound and on the surface o f  the 
surgical implants in order to prevent osteomyelitis.
Since osteomyelitis is a progressive destructive process, accurate and early 
detection is necessary. Physical examination o f the wound and microbiology o f the bone 
biopsy are the two modalities used in combination to diagnose osteomyelitis. Swelling, 
redness, drainage from the wound, and deep chronic pain are common symptoms o f this
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disease. Bone fragmentation and necrosis with purulent drainage are the strong 
indications o f the bone infection. Imaging techniques such as x-ray and CT scans are 
used to know the extent o f  debridement within the body.
To treat osteomyelitis efficiently, both medical and surgical methods are used 
either individually or in combination, depending upon the severity o f the infection. The 
choice o f antibiotic therapy depends on microbiology o f bone biopsy. If the microbiology 
cannot be determined, broad spectrum antibiotics are administered parenterally for 5-6 
weeks and then a prolonged course o f oral administration is suggested. When antibiotic 
therapy is not adequate and a considerable amount o f necrotic tissue is present, a surgical 
intervention o f the wound is necessary. A surgeon cuts open the wound and removes all 
the necrotic bone and infected soft tissue around it. Despite the use o f surgical 
intervention and prolonged course o f antibiotic therapy, chronic recurrence o f 
osteomyelitis is about 30% within a year o f primary treatment [44], To avoid this 
recurrence, the surgeon fills the resected area with antibiotic loaded spacers that elute 
antibiotics for an extended period o f time preventing the biofilm formation and thus 
avoiding chronic recurrence o f osteomyelitis [45].
2.4 Osteoporosis
Osteoporosis is a systemic bone disorder represented as one o f  the major health 
problem in the medical field. It is a skeletal disease characterized by a decrease in bone 
mass and deterioration o f  osseous tissue resulting in increased risk o f bone fractures [46]. 
It occurs in both middle aged males and females, but is most common in post­
menopausal women [47], Depending upon the etiology, this disorder is classified as 
primary and secondary osteoporosis. Primary osteoporosis, also known as senile
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osteoporosis, is caused by aging and accelerates at menopause. Its etiology is not clearly 
understood. Secondary osteoporosis is caused by nutritional factors and medical 
conditions such as hypogonadism, endocrine or hematological disorders, and auto­
immune diseases [48],
Currently, about 200 million people suffer with osteoporosis worldwide. 
Approximately one-third o f the female population above 60 years o f age are commonly 
affected [49]. Several clinical studies have demonstrated that primary cause o f 
osteoporosis in post menopausal women is due to sex-hormone deficiency, particularly 
due to estrogen deficiency [50]. Estrogen deficiency leads to down regulation o f pro- 
inflammatory cytokines synthesis leading to increased formation o f pre-osteoclast cells. 
These pre-osteoclast cells resorb bone minerals into blood causing osteoporosis. 
Approximately 2% o f bone loss per year occurs within the first couple o f years after 
menopause, clearly increasing the risk for fracture [51].
Long term Hormone Replacement Therapy (HRT) is generally prescribed to treat 
osteoporosis in elderly women. Estrogens are a group o f female sex hormones 
responsible for the development and maintenance o f  normal sexual characteristics and 
functions. The three main types o f estrogens are estrone (E l), estradiol (E2) and estriol 
(E3). E2 is the major estrogen produced in the ovaries and, in small quantities, in the 
adrenal glands and fat cells. It is the most active and predominant form o f all estrogens 
and is responsible for most o f the estrogenic effects. E2 and El are interconvertible. El is 
less potent than E2 and is mostly produced by adipose cells. E3 is secreted during 
pregnancy by the placenta and is the least potent o f  all the hormones. Depending upon the
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individual hormone levels, HRT is prescribed as either estradiol alone or in combination 
with other hormones such as E l , E3, and progesterone.
2.5 Calcium Phosphate Bone Cements
Brown and Chow were the first to propose the use o f calcium phosphate cement 
in bone repair [52], In 1920, Albee reported the first successful medical application o f 
calcium phosphate bio-ceramics in humans [52]. These cements are easily moldable, set 
at physiological temperatures, and have HA as their end product. These properties make 
them advantageous over other cements in the market. In addition, HA (its end product) is 
easily resorbed by the osteoclast cells leading to new natural bone formation at the bone- 
implant interface. This process is called osteotransductivity [53].
All CPCs are formulated by mixing a solid and a liquid component. The solid 
component consists o f two or more calcium phosphate salts. The liquids can be water, 
alginates, chitosan, or sodium phosphates. To obtain maximum biological use, these 
components are mixed in predetermined proportions to form HA. Resorbability o f the 
CPCs completely depends on its end product [4], The physicochemical reactions that 
occur during mixing are complex.
The solid phase usually consists o f a basic and an acidic salt, which react together 
in an aqueous medium and precipitates HA as a final product. In Eq. 1, Tetra-calcium 
phosphate (TTCP, Ca4(P04)20 ,  basic salt) reacts with p-Tri-calcium phosphate (p-TCP, 
Ca3(P 0 4)2, acidic salt) in the presence o f water and precipitates HA (Caio(P0 4 )6(OH)2), 
whereas in Eq. 2, TTCP reacts with Di-calcium phosphate dehydrate (DCPD, 
CaHP0 4 .2 H20 ), an acidic salt in an aqueous medium and precipitates HA [54].
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Ca4(P0 4 )2 0 +2Ca3(P0 4 )2+H2 0 -> C a1(,(P0 4 )6(0 H)2 Eq. 1
2Ca4(PO4)2O+2CaHPO4.2H2O^Cai0(PO4)6(OH)2+4H 2O Eq. 2
In this process, water is a dissolving agent and is not a reactant in the setting 
process. It allows dissolution o f particles and precipitation o f the products. Relatively low 
strength, high brittleness, inadequate adaptability in clinics, and a high possible rate o f 
dissolution at the initial setting stages due to formation o f unstable phases are common 
disadvantages o f water when used as a setting liquid [55], These properties o f water limit 
its use in clinical applications. It cannot be used for treating defects with bleeding or with 
the continuous flow o f tissue liquids, like saliva, nor can it be used where the bone defect 
is at mechanical load bearing site.
Adding water soluble biocompatible polymers in the calcium phosphate cement 
either in the liquid or solid form increased properties such as cohesion, toughness, 
biological response, and resorption o f  material [56]. If the cement does not set and 
disintegrates, it provokes an inflammatory response and may lead to cell apoptosis at the 
site o f cement application [57].
The introduction o f gelatin or chitosan as a mixing liquid can affect the kinetics o f 
setting and hardening o f  CPCs [58]. Chitosan is a linear copolymer o f N-acetyl D- 
glucosamine and o f  D-glucosamine [54]. An increase in flexural strength o f CPC 
composite reported when 15-20 wt% chitosan was incorporated in it [54, 56], No 
cytotoxicity was found in chitosan containing CPCs. In addition, a considerable increase 
in ALP activity was observed when mesenchymal stem cells were cultured on TTCP- 
DCPA composite [56]. These bioactive properties have led to an increased use o f 
chitosan in CPC.
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Cement setting time depends on factors such as solid-liquid composition, liquid- 
to-powder ratio, and particle size o f the powder. Setting conditions also influence the 
mechanical properties o f the cement [59],
2.6 Nanoparticle Technology
Pathogens, even a small fraction, can induce devastating effects on humans. 
Antibiotic usage is an effective treatment for infections. However, recurrence o f the 
infection is commonly seen and it tends to develop into a chronic problem in no time. In 
order to guarantee sufficient protection against microbes, developing novel therapeutic 
approaches to treat infections is o f utmost importance [60]. The use o f nanoparticle 
technology as a drug delivery system is a well established strategy for enhancing the 
bioavailability, allowing targeted drug delivery and improved therapeutic efficacy. 
Currently, many nanoparticles are under investigation for the treatment o f diseases, more 
specifically for chemotherapeutic and antibiotic drug delivery. Due to unique features, 
such as large surface to mass ratio, ability to load a vast variety o f compounds and 
biocompatibility, nanoparticles such as Carbon Nanotubes (CNT) and Halloysite 
Nanotubes (HNT) are widely used for medical purposes.
CNTs are graphite sheets commonly found as single-wall nanotubes (SWNTs) 
and multi-wall nanotubes (MWNTs). Due to their good mechanical, electrical, and 
electrochemical properties, they are widely used as biosensors [61]. Though CNTs are 
potential carriers for drug delivery, they cause toxicity due to the presence o f ferric 
impurities, degree o f functionalization, physical form, and agglomeration state [62], 
Research conducted by Yang et al. on mice showed adverse effects due to accumulation 
o f CNTs in major organs, such as the liver, spleen and lungs [62, 63]. Due to their high
2 0
cost, reduced availability and toxic effects, CNTs are less likely to be used than other 
nanotubes.
HNTs are commercially inexpensive, bi-layered aluminosilicate nanotubes found 
naturally as raw mineral deposit. These are commercially made by dehydrating 15-20 
clay layers, which rolls up to form a hollow tubule capable o f carrying drugs. The inside 
o f the lumen is positively charged, and the external surface is negatively charged, 
permitting additional functional modifications o f these surfaces. This charge on both 
outer and inner surfaces affects the efficiency o f  loading the drugs and other chemical 
agents. Substances with overall negative charge can be easily loaded into the lumen when 
compared to positively charged particles. The size o f HNTs varies from 500-1000 nm 
with an inner diameter o f 15-100 nm depending on the deposit [64],
Due to physical properties such as nanosized lumens, high L/D (length to 
diameter) ratio, low hydroxyl group density, low cost and abundant natural deposits, 
HNTs are studied as sustained drug releasing agents. They also reported improved 
mechanical performances and stability when used in the fabrication o f polymer 
nanocomposites [65], Loading HNTs with pharmaceuticals showed low initial release 
concentrations, preventing an initial outburst and uniform drug delivery (particularly with 
drugs, such as antibiotics, chemotherapeutics, hormones and other growth factors). The 
drugs gentamicin sulfate, nitrofurantoin, dexamethasone, furosemide and nifedipine gave 
an extended 6-10 hr release profile [66]. Under optimal conditions, a maximum loading 
o f 12% volume (very close to theoretical capacity) was obtained [66]. When HNTs are 
added without an active agent, they act as skin-cleansing agents due to adsorptive
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properties. HNTs adsorb dead skin cells and unpleasant oils from the skin, resulting in a 
fresh and healthy look [67].
2.7 Additive Manufacturing
3D printing is a process o f making three-dimensional objects from a digital file. It 
can be achieved by either subtractive or additive manufacturing. In subtractive 
manufacturing, an object is created by removing sections from a block o f material by 
cutting or drilling away the excess material. This type o f prototyping is limited by cutting 
and routing technology, cannot create hollow parts from a single block o f material, and 
generates excess material waste [68], In additive manufacturing, the product is created by 
adding materials layer by layer until the final product is obtained. As shown in Figure 
2- 1, the desired construct is built by assembling many thin cross sectional layers, offering 
the ability to build complex and intricate designs [69]. Since the object is made in layers, 
a slicing software is required to slice the object’s digital file into multiple layers. Each 
layer can be then analyzed separately and the set o f  instructions given to the machine can 
be customized as necessary. Depending on the form o f material used, this process is 
categorized into solid based, liquid based, and powder based manufacturing. Presently, 
selective laser sintering (SLS), stereolithography (SLA), fuse deposition modeling 




Figure 2-1: Types o f rapid prototyping [69],
SLS uses high power laser beam to selectively fuse powdered materials (plastic, 
metal, ceramic or glass powders) into a desired 3D object [70]. Here, the laser beam act 
as a heat source to sinter the powders in pre-determined size and shape. After the first 
layer is selectively sintered, rollers deposit the second layer o f loose powder from the 
feed bins, as shown in Figure 2-2, and the process is repeated from bottom to top until 
the desired object is formed.
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Figure 2-2: Selective Laser Sintering (SLS).
The performance o f SLS process depends on laser power, thickness o f the powder 
layer, roller speed and print bed’s heating/cooling rate [71]. A wide range o f materials
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can be used for this process and the unused powder can be recycled. In order to avoid 
oxidation and to maintain the process at a constant melting point temperature, an inert gas 
atmosphere must be maintained [72],
SLA is a liquid based additive manufacturing process which uses precise and 
sufficiently powered UV laser beam to solidify photo-reactive polymer resin. Laser beam 
illuminates the surface o f the resin in the shape o f  the desired object, as shown in Figure 
2-3, resulting in solidification o f polymer and adhering to the platform. Once the first 
layer is solidified, the support platform descends, allowing the liquid resin o f calculated 
thickness to flow over the built layer and the process is repeated until desired artifact is 
built [73]. Excess liquid resin is drained or re-used. For better mechanical properties, 
finished objects are often exposed to the UV light, a process called post resin-curing. This 
process is limited only to photosensitive polymers such as low-molecular weight poly 
acrylate and epoxy macromeres.
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Figure 2-3: Stereolithography (SLA).
FDM is a solid based additive manufacturing technique. It builds 3D objects by 
depositing thin layers o f thermoplastic filament on to a platform in layer-by-layer fashion
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as shown in Figure 2-4. Plastic filaments including Acrylonitrile butadiene styrene 
(ABS), Polylactic acid (PLA), Polyamide (Nylon), Polyethylene terephthalate (PET), and 
Thermoplastic polyurethane (TPU) are commonly used for FDM. This method does not 
need any chemical post processing or resin-curing. Due to their cost effectiveness and 
wide range o f material use, this type o f prototyping is advantageous over others and is 
widely used. In this current study, 3D printer based on FDM principles are used.
In LOM, layers o f  adhesive-coated material is glued together and cut into the 
required shape using a laser beam to obtain a 3D object. Materials used in this process 
include glued paper, plastic and metal sheets. A heated roller runs through a thin layer o f 
adhesive material to make sure it adheres to the substrate properly as shown in Figure 
2-5. A laser cutter traces through the sheet into the desired shape and then another layer










Figure 2-4: Fused Deposition Modeling (FDM) [74],
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o f the material is rolled over it. This process is repeated until the final artifact is built. 
Since the objects printed have wood like characteristics, this process is used to make 
relatively large subjects and additional drilling and machining o f the parts are required. 
As paper and glue are used in this process, external factors like temperature and humidity 
affect the structure and composition o f the part.
FDM is an additive manufacturing technology developed by Scott Crump in the 
late 1980s. Later in 1990, Stratasys Inc. patented and commercialized it as a technology 
[76], In this process, a plastic filament is melted through a nozzle tip o f the required 
diameter and laid on a platform in layer-by-layer fashion to build a three dimensional 
construct o f the required shape as shown in Figure 2-4 [74], Plastic filaments including 
Acrylonitrile butadiene styrene (ABS), Polylactic acid (PLA), Polyamide (Nylon), 
Polyethylene terephthalate (PET), and Thermoplastic polyurethane (TPU) are commonly
S h e e t m a te n a lB lo c k
P h u fo iii)
Figure 2-5: Laminated Object Manufacturing [75].
2.8 Fused Deposition Modeling (FDM)
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used for FDM. A computer aided design (CAD) model is used to guide the nozzle tip 
accordingly to lay the material in the required shape.
For a 3D CAD model to be printed as 3D object, it has to go through the 
following steps as shown in Figure 2-6.
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Figure 2-6: Steps involved in making a 3D object from a CAD model.
2.8.1 Stereolithography Files (STL)
STL also has several backronyms such as “Standard Tessellation Language” and 
“Standard Triangle Language” . In order to interact with FDM machines, data files are 
saved as STL file format. It is a triangulated representation o f  a 3D CAD model. This 
format approximates the surface o f an object with many triangles. For a simple object 
like a cube as shown in Figure 2-7, its surface is approximated with 12 triangles. As the 




Figure 2-7: A) 3D model o f a cube, B) STL format o f a cube, C) STL file of a
complex design.
Most o f the CAD software currently available are capable o f producing an STL 
file. AutoDesk, Solidworks, IronCAD are some o f the widely used CAD software for 
making an STL model.
2.8.2 Computer Aided Design (CAD)
CAD is a program which helps users to create STL files. It helps in designing, 
analyzing and optimizing 3D models. This software helps in designing ideas and 
visualizing the concepts through photorealistic renderings. They also simulate the 
performance o f the design in the real world. Solidworks 2015 and AutoCAD are the two 
softwares used in this research to design constructs o f required shape and dimensions.
2.8.3 Sheer
Slicer is a software which cuts a CAD model into many horizontal slices (layers). 
It generates tool path by converting the design data into movement o f the filament 
deposition head o f  the 3D printer along the X, Y, and Z axis over the build area. Printing 
parameters such as deposition head speed, rate o f material flow from the head, and 
cooling fan speed can be modified according using this software. In the current research, 
slic3R and ReplicatorG were used for slicing the designed constructs.
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2.9 Applications o f 3D Printing in Implant Technology
High degree o f  freedom to produce custom medical devices is the greatest 
advantage o f  a 3D printer in the biomedical field [77]. This technology has been applied 
in the medical field since the early 2000, when custom dental implants and prostheses 
were first 3D printed and implanted surgically [78], In 2011 Kaiba Gionfriddo, a six 
months old boy form Ohio, stopped breathing and turned blue. He was diagnosed with a 
rare condition called tracheobronchomalacia in which periodical collapse o f the windpipe 
due to weakening o f tracheal cartilage was observed, preventing him from normal 
breathing. Dr. Glenn Green, an associate professor o f pediatric otolaryngology and his 
colleague Dr. Scott Hollister, professor o f biomedical engineering and associate professor 
o f surgery at the University o f Michigan, were able to 3D print a custom tracheal-splint 
implant from CT scan data o f the patient’s trachea. These splints were made on a laser- 
based 3D printer using biodegradable polymer and was surgically implanted into the 
patient. The splint printed had a slit along its length in order to expand as the child grows. 
The baby recovered and within three years a full resorption o f  the implant occurred. 
Before this procedure, newborn babies with tracheobronchomalacia had no cure and little 
chance o f  survival. Now this procedure was patented and successfully replicated with 
three other babies having similar conditions [79].
Since Kaiba’s story, 3D printing for biomedical applications has been gaining 
more importance. Customization o f  implants and surgical tools can have a positive 
impact on the success o f  the surgery, time required for surgery, and patient recovery time 
[80]. Another benefit o f this technology is the ability to build the objects at low cost on a
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small-scale production. The following are some o f the applications o f 3D printing in 
biomedical engineering.
2.9.1 Bioprinting Tissues and Organs
Allotransplantation from either a deceased or living donor is the current treatment 
for organ or tissue failure. There is always shortage o f human organs available for 
transplant. Additionally, finding tissue which matches the host body is a difficult task.
For the organ donor shortage, tissue engineering and regenerative medicine are 
considered as potential solutions. In tissue engineering, pluripotent cells are isolated, 
multiplied by adding external growth factors, seeded onto scaffolds, inducing cell 
differentiation and developing into a required functioning tissue [81]. 3D bioprinting 
offers additional advantages to this method by highly customizing the parameters such as 
precise placement o f cells, cell concentration, drop volume and diameter o f printed cells 
[82]. In this technology, print head is filled with living cells and are deposited onto the 
substrate to reproduce tissue or organ. To fabricate a heterogeneous tissue or organ, 
multiple print heads each filled with different types o f cell lines can be used. Researchers 
at Cornell University used this technique to fabricate a living aortic valve that have 
similar anatomical features as that o f the native valve. They used multiple print heads 
filled with smooth muscle cells and valve-interstitial cells suspended in an alginate- 
hydrogel system. They could successfully fabricate living heart valve conduits with a 
strong resemblance to the original value [83].
Similarly, many researchers have provided proof o f concept to build bone, 
cartilage, spinal discs, artificial ear, and other types o f  tissues using bioprinting.
However, if  the bioprinted tissue has a thickness greater than 200 pm, the oxygen
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diffusion between the host and transplanted tissue will be limited. In order to avoid this, 
organs with precise vascular network should be bioprinted, which has not yet been done 
[78],
2.9.2 Customized Implants and Prostheses
Traditionally, a surgeon had to modify standard implants according to the 
patient’s anatomy by cutting pieces o f metal/plastic to a desired shape, size and fit. 
Currently, CAD programs can convert digital files such as x-ray, MRI or CT scan into 
STL files and can be easily printed used a 3D printer. Due to this ability, 3D printing 
technology has been used in the health care sector to print complex, customizable 
prostheses and implants. For the first time technicians at the Biomedical Research 
Institute o f Hasselt University in Belgium, 3D printed a titanium mandibular prosthesis 
and successfully implanted it to an 83-year-old woman [84], This implant was made by 
fusing layers o f titanium powder using a high power laser beam. In 2013, FDA approval 
for 3D printing polyetherketoneketone (PEKK) was received by Oxford Performance 
Materials and a skull implant was successfully printed and implanted in the same year 
[84],
The ear canal is structured differently in every individual and use o f 3D printing 
allows making customizable ear prosthesis efficiently and cost-effectively. Using 
biomaterials such as silicon, silver nanoparticles and chondrocytes suspended in collagen, 
a prosthetic ear which can detect electromagnetic frequencies and anatomically similar to 
a human ear has been 3D printed successfully [85]. Use o f  3D printing in orthodontics 
made the dental procedures cheaper and more efficient. To make dentures, crowns and 
bridges, all that is needed is a 3D digital scanner and a 3D printer. This process skips the
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step o f casting physical molds o f patient’s oral cavity and makes the surgical procedures 
less invasive and more accurate.
2.9.3 Anatomical Models and Tools for Surgical Preparations
Gaining insight into a patient’s anatomy prior to a surgical procedure is o f utmost 
importance for a successful surgery. Current imaging procedures such as MRI, CT scans 
and x-rays, which are viewed in 2D, are the only source to study and simulate surgery. 
Cadavers are also used for this purpose, but they lack appropriate pathology and provide 
more o f  an anatomy lesson than a representation o f surgical procedure [77, 85], Using 3D 
printer tangible models with exact patient specific anatomy can be printed. In Kobe 
University Hospital, Japan, surgeons started using 3D printed replica’s o f patient’s liver 
to determine how to best carve a donor liver with minimal tissue loss, preserving its 
function and to best fit it in the abdominal cavity. In complex cases, like in neurosurgery, 
where a small error can even lead to potentially devastating consequences, 3D models 
with exact anatomy o f the patient will help a lot in studying the case thoroughly and 
simulate surgery prior to operating on the patient. Clear or partially transparent materials 
with water content and texture similar to human tissues such as acrylic resins or polyvinyl 
alcohol were used to maximize the simulation conditions [78],
2.10 Biopolymers
Polymers were first synthesized from glycolic acid in the 1920s. At that time, 
polymer degradation was viewed negatively since they have a tendency to deteriorate 
eventually and are not suitable for long-term industrial uses [6]. However, this instability 
has proven to be greatly important in the medical field in the last four decades. In the late 
1960s, the application o f biodegradable implants using PLA biopolymer was introduced
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by Kulkami et al. [5], Later in 1984, Rokkanento first used this material as the internal 
fixation device for treating fractured ankles [86]. Since then, many polymers such as poly 
lactic acid (PLA), polyglycolic acid (PGA), polyethylene glycol (PEG), poly (glycolide- 
co-lactide) (PLGA), and other lactic/glycolic copolymers have been used for medical 
purposes. An ideal bioimplantable polymer must be easily sterilizable, does not evoke 
any inflammatory reaction, and should be metabolized in the body completely without 
leaving any traces [6],
Traditionally used metal implants have been clinically efficacious, but they are 
excessively stiff, stay at the site o f implantation permanently, need secondary revisions, 
and require surgical removal upon healing [5]. Biopolymer implants do not need 
additional or revision surgery, available in different forms and can be customized into 
different shapes and and compositions.
2.10.1 Types o f  Biopolymers
Biopolymers and bioplastics are often confused for one another. Polymers that are 
obtained from renewable sources are biopolymers and synthetic materials manufactured 
from biopolymers are called as bioplastic. Based on their origin, biodegradable polymers 
are classified as natural and synthetic polymers.
2.10.1.1 Natural Biodegradable Polymers
Collagen and chitosan are the two major natural biodegradable polymers available 
abundantly and widely used. In addition to those, fibrin, gelatin, chitin, silk and starch are 
the other natural polymers been under research interest currently. Collagen is a high 
molecular weight polymer (M „=300 KDa) with a long helical shaped structure (length = 
300 nm). It is enzymatically degraded by collagenase enzyme in the body. The rate o f
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degradation can be customized by altering the cross-linkings in the polymer chain. Its 
osteoinductive, osteoconductive, and osteogenic properties have led to a wide use in bone 
implant technology. Because a large portion o f  human bone minerals consists of HA and 
collagen, collagen is coupled with other biomaterials such as calcium phosphates to 
obtain a complete biomimetic system for osseous replacement [87],
Chitosan is a linear polysaccharide made o f glucosamine and N-acetyl 
glucosamine. Depending on the processing method and its source, it has a molecular 
weight ranging from 250 to 1000 KDa. Chitosanase degrades this polymer in vitro. In 
vivo degradation is regulated by hydrolysis o f acetylated residues in the presence o f 
enzyme lysozyme. The biodegradation o f chitosan depends on its molecular weight and 
degree o f  polymer crystallinity [88, 89], Its good mechanical properties and 
osteoconductivity have led to increased use in calcium phosphate cements for orthopedic 
surgery. Researchers have shown that the scaffolds made o f calcium phosphate cements 
mixed with nano-crystalline chitosan have 20-fold greater surface area and roughness 
when compared with calcium phosphate cements alone [90].
2.10.1.2 Synthetic Biodegradable Polymers
Among synthetic biodegradable polymers, Poly (a-hydroxy acid) class polymers 
are most extensively investigated and widely used. PLA, PGA and PLGA are few o f the 
biopolymers o f  this class used extensively for medical purposes. Their biodegradable and 
biocompatible nature account for their wide use in implant technology. These polymers 
undergo in vivo degradation through de-esterification process mediated by hydrolysis and 
the monomer end products are removed through excretory pathways [91, 92], Several 
factors including crystallinity, chemical structure and composition, physical dimensions
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o f implant, surface area and site o f implantation affect the rate o f polymer 
biodegradation.
PLA is an aliphatic thermoplastic polyester which melts around 175°C and has a 
glass transition temperature o f 60-65°C. It is formed by the polymerization o f cyclic 
diester o f  lactic acid (lactide). Lactide exists in two optical isomer forms, D and L- 
lactide. PLA made from L-lactide are more crystalline in nature and biodegrade at a low 
pace when compared to PLA made out o f D-lactide. Due to this reason L-PLA is used 
more in orthopedic surgeries. Wide use o f this polymer, than any others, is due to its 
excellent mechanical and thermal properties added with biocompatible and biodegradable 
nature. PLA in the body is hydrolyzed into lactic acid, which enters into citric acid cycle 
and subsequently excreted as carbon dioxide from the lungs [93], Research conducted by 
Brady et al. showed an absorption rate o f about 1.5 years for 50-90 mg o f radiolabeled 
PLA implanted in a rat’s abdominal wall [94]. In another research, L-PLA bone implants 
attached to a sheep femora showed small traces o f the polymer still after 4 years o f 
implantation [95]. However, in both cases, PLA is well tolerated by the surrounding 
tissue and most o f the polymer is primarily metabolized through respiration.
PCL is a semi-crystalline aliphatic polyester, melts at 65°C and has a glass 
transition temperature o f  -60°C. It is formed by the ring opening polymerization process 
o f  e-caprolactone. In the body, PCL degrades in two phases. It first undergoes hydrolysis 
o f esters bonds and form fragments o f  caprolactone oligomers. These oligomers are then 
engulfed by macrophages and they undergo degradation inside phagosomes by lysozyme 
enzymes [95]. Since this polymer exhibits low mechanical strength, its use in implant 
technology is limited to non-load bearing regions only.
CHAPTER 3
NANO-ENHANCED CALCIUM PHOSPHATE BONE CEMENTS
Currently available PMMA bone cements cause tissue damage around the 
bone/cement interface due to the release o f toxic methylmethacrylate (MMA) monomers 
[96, 97]. These cements exhibit a high exothermic setting temperature ranging from 70°C 
tol20°C  [98]. In an experiment conducted by Stancyk and Rietbergen, on bovine 
cancellous bone, the temperature exposure o f 70°C by a fraction (10%) o f the bone at 
bone/cement interface was recorded [99], In addition, PMMA cements lack elasticity and 
have dense structure which does not allow bone growth inside the cement.
CPCs, on the other hand, are osteoconductive and osteogenetic [57]. They set 
endothermically at body temperature. They have even shown an x-ray diffraction spectra 
similar to the mineral phase o f the bone [4], In addition low shrinkage, durability, density 
or porosity (depending on site o f  injury), and formability (ability to fill cavities of 
complex configurations) are positive qualities o f  CPCs [55].
Risk o f contamination is common in all implantable biomaterials used. The 
objective o f the present study is to increase the mechanical properties o f the CPCs along 
with inculcating anti-infective properties to it. HNTs were used to enhance mechanical 
properties and to introduce anti-infective nature to the CPCs. The basic foundation for 
this work was a part o f  a group project with Uday Jammalamadaka. Data obtained from 
mechanical testing and SEM were shared with Uday Jammalamadaka.
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3.1 Materials and Methods
Different compositions o f calcium phosphate salts were mixed, and formulated 
CPCs were tested for their compression strengths. Formulation with highest compression 
strength was selected and further used. HNTs were loaded with antibiotics: Gentamicin 
Sulfate (GS) and Neomycin sulfate (NS). Surface morphology was studied using SEM 
imaging. For evaluating mechanical properties, compression testing and flexural testing 
were conducted. Escherichia coli and Pseudomonas aeruginosa were used to evaluate the 
anti-infective properties o f the HNT loaded CPCs.
3.1.1 Materials
Calcium phosphate dibasic anhydrous (H C a04P, DCPA, Catalog no. 21177), (3-tri 
calcium phosphate (Ca3 0 sP2, (3-TCP, Catalog no. 16483), calcium phosphate monobasic 
monohydrate (H4CaOsP2.H20, MCPM, Catalog no. 21053), chitosan oligosaccharide 
lactate (Catalog no. 523682), chitosan (low molecular weight. Catalog no. 448869), 
polycaprolactone (CfTLoCh, PCL, Catalog no. 440744), calcium L-lactate 
(CfdLoCaOfi.xEhO, Catalog no. L4388), HNTs (Catalog no. 685445) were from Sigma- 
Aldrich, St. Louis, MO. Tetra calcium phosphate (Ca40 4P, TTCP, Catalog no. 010813A) 
was ordered from CaP Biomaterials, E. Troy, WI. Cupric chloride (CuCl2, Catalog no. 
SA09487M) and calcium carbonate (CaCOj, Catalog no. SA09409M) were delivered 
from Nasco, Fort Atkinson, WI. Sodium phosphate dibasic (Na2HP04, Catalog no. 
7782856) was from Fisher Scientific Company, Waltham, MA.
3.1.2 Formulation o f  CPCs
Different types o f calcium phosphate salts were mixed in different proportions 
using various liquid phases and were labeled as shown in Table 3-1.
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All samples were hand mixed, using mortar and pestle, under ambient conditions 
(room temperature and atmospheric pressure). The powder phase was mixed thoroughly 
until all o f the salts were uniformly dispersed. To this phase, the liquid phase was added 
in small quantities and triturated until the mixture became a thick, moldable paste. This 
paste was molded into compression cylinders o f 6 mm in diameter and 12 mm in length 
in accordance with ASTM F451-99a [100], These samples were left to set for 24hours, 
then removed from the molds.
The compression testing was performed using ADMET expert 2600 universal 
testing machine with an axial cross-head speed o f 1 mm/min [54]. To minimize the error, 
five samples for each formulation were tested and an average was calculated. The 
formulation with the best compressive strength was chosen and used for further testing.
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Solid phase (weight in gm) Liquid phase 
(volume in ml)
1 MCPM (2) Na2HP04(l)
2 DCPA (2) Na2HP04(l)
3 MCPM (1) + DCPA (1) Na2HP04(1.8)
4 CaC03(1.5) + MCPM (0.5) Na2HP04(1.5)
5 MCPM (1) + DCPA (1) + HNTs (7%) Na2HP04 (0.6)
6 MCPM (1) + DCPA (1) + HNTs (5%) Na2HP()4 (0.6)
7 DCPA (2) + PCL (5%) Na2HPO4(0.6)
8 MCPM (0.4) + DCPA (0.4) + p-TCP (0.1) + Chitosan 
(0.1)
Na2HP04(1.6)
9 MCPM (0.4) + DCPA (0.4) + p-TCP (0.1) + Na2HP04(1.6)
10 MCPM (0.45) + DCPA (0.45) + P-TCP (0.1) Na2HP04 (0.9)
11 MCPM (0.45) + DCPA (0.45) + p-TCP (0.05) + HNTs 
(0.05)
Na2HPO4(0.9)
12 MCPM (0.75) + DCPA (0.75) + CaCO,(0.5) Na2HPO4(0.9)
13 MCPM (0.45) + DCPA (0.45) + CaCO3(0.5) + 
Chitosan (0.5)
Na2HP04 (1.2)
14 MCPM (0.47) + DCPA (0.48) + CaCOj (0.5) Na2HP04(1.2)
15 MCPM (0.5) + DCPA (0.5) Na2HP04 (0.4)
16 MCPM (0.5) + DCPA (0.5) Na2HPO4(0.4) + 
PCL (0.4)
17 MCPM (0.4) + DCPA (0.4) + PDDA (0.2) 1% Chitosan (1.2)
18 MCPM (0.4) + DCPA (0.4) + Alginate (0.2) 5% Chitosan Lactate 
(1.2)
19 TTCP (1.5) + DCPA (0.5) 5% Chitosan lactate 
(1.4)
20 MCPM (0.4) + DCPA (0.4) + P-TCP (0.1) + PDDA 
(0.1)
10% Chitosan lactate 
(1.4)
21 TTCP (1.5) + DCPA (0.5) 10% Chitosan lactate 
(1.2)
22 TTCP (1.4) + DCPA (0.4) + p-TCP (0.2) 10% Chitosan lactate 
(1.2)
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Molds o f  inner dimensions 65 mm x 10 mm x 4 mm were prepared using 
paraffin wax in accordance with the ASTM F417-78 standards [101]. Using the same 
machine, flexural strength, using three-point bending test, was conducted at a cross-head 
speed o f 0.75 mm/min with 20 mm distance between two consecutive points. Three 
samples for each concentration o f HNTs were used and an average was calculated.
Flexural strengths o f CPCs were calculated using the formula in Eq. 3 and the 
peak force values obtained from the three-point bending test:
_  3 FL Eq. 3
~~ 2b d 2 '
where a  is the flexural strength; F is the peak force; L is the distance between extreme 
points; b is the sample’s width; d is the sample’s height.
For cell-culture techniques, specimens 5 mm x  1 mm were made using steel 
molds. The liquid phase used in this process was prepared from sterile deionized water. 
After setting, the samples were removed from the molds, dipped in alcohol and dried 
under a class II hood. Samples o f  size 5 mm X 1 mm were cast in steel molds, then 
alcohol treated and dried for use in bacterial culture studies.
3.1.3 Loading HNTs
A 500 mg o f Gentamicin Sulfate (GS) (Catalog no. G3632, Sigma, MO, US) was 
dissolved in 10 ml o f deionized water, then sonicated until the drug was completely 
dissolved and a clear solution was formed. To this solution, 1 gm o f HNT powder was 
added and sonicated for 30 minutes. This solution was then kept under the vacuum for 20 
minutes, then kept at room atmosphere for 20 minutes. This process o f alternate vacuum 
and room atmosphere was repeated three times. It was then washed with water to remove 
the drug on the surface o f the HNTs and dried under open air, until it took a powder form.
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The same procedure was followed for loading Neomycin Sulfate (NS) (Catalog no. 
21810031, Gibco, NY, US).
3.1.4 Mechanical Properties
Different concentrations o f HNTs were added to the strongest formulation and 
tested for both compression and flexural strengths. Data from these samples were 
compared. Figure 3-1 shows the ADMET expert 2600 universal testing machine used to 
test the mechanical properties o f the CPC scaffolds.
Figure 3-1: Admet 2600 Dual Column Bench Top Universal Testing Machine.
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3.1.5 Scanning Electron Microscopy (SEM)
To observe the surface properties o f the CPC samples, a scanning electron 
microscope was used. Images were taken o f the fracture interface o f  the cement samples 
using a S4800 Field Emission SEM, HITACHI Scanning Electron Microscope. A 3 nm 
layer o f gold was coated on to the surface o f the scaffolds prior to imaging to make the 
samples conductive. Images were taken for samples with and without HNTs, and also for 
different concentrations o f HNTs in CPC scaffolds.
3.1.6 XTT Assay
XTT or (2,3-Bis-(2-M ethoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5- 
Carboxanilide) is a sensitive and reliable quantitative assay. It is a colorless or slightly 
yellow color tetrazolium dye which gets converted into bright orange color formazan 
upon reduction. When this dye is used in cell cultures, the dehydrogenase enzymes 
produced from the mitochondrial cycle o f  actively respiring cells reduces the dye to an 
orange color formazan. This assay is greatly improved by adding an electron accepting 
agents such as PMS (N-methyl dibenzopyrazine methyl sulfate). Unlike MTT, this assay 
does not require to go through laborious procedures such as solubilization prior to 
quantization, making this process quick and easy.
To check the cytocompatibility o f  the formulated scaffolds, XTT was performed 
on Human Osteoblast Cells (HOB) C-12760 purchased from PromoCell, Heidelberg, 
Germany. XTT assay kit (X4751) with 1% PMS was ordered from Sigma-Aldrich. CPC 
discs o f 5 mm x  1 mm dimensions were molded using different concentrations o f HNTs
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(5%, 10% and 15%). Control discs without any HNTs and blank cell lines were also 
cultured for comparative studies.
Osteoblast cells, upon reaching to 90% confluency, were trypsinized and re­
suspended into culture media. In a 96 well plate, 100 pi o f cell suspension was added in 
each well and incubated for 24 hours. Activated XTT solution (20 pi) was then added to 
each well and incubated for 2 hours and optical densities were measured using Phenix 
LT-4000 absorbance microplate reader at 450 nm.
3.1.7 Drug Release Profile
A total o f 50 mg o f loaded HNTs (GS and NS separately) were transferred to 1.5 
ml eppendorf tubes. Simulated body fluid (SBF, 1 ml) was added and placed on a rocker 
for continuous movement o f the liquid. Samples were collected at 5, 10, 15, 20, and 30 
minutes, as well as 1 ,2 ,4 , 6, 12, and 24 hours for the first day and then one sample a day 
for 7 days. To avoid HNTs in the collected samples, eppendorf tubes were centrifuged for 
2 minutes at 5000 rpm. The same amount o f fresh SBF was replaced into the tubes each 
time the sample was removed and was vortexed until the sediment o f  HNTs was 
redispersed. The same procedure was followed for sampling the CPC scaffolds. Discs o f 
10 mm x  2 mm were used for the drug release profiles.
As GS cannot be detected directly by UV-Visible spectroscopy, an indirect 
method o f detection by ophthalaldehyde reagent was used. This reagent was prepared by 
adding 250 mg o f ophthalaldehyde powder (Sigma, MO, US) to 6.25 ml o f 95% 
methanol. This mixture was sonicated for 30 minutes until a clear solution was obtained. 
0.3 ml o f 2- hydroxy ethyl mercaptan (Catalog no. M6250, Sigma, MO, US) was added 
to 56 ml o f 0.04 M sodium borate (Catalog no. B9876, Sigma, MO, US) and mixed
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thoroughly [102], Both o f these mixtures were added, then sonicated for 15 minutes 
before being stored in an amber color container for 24 hours. A total o f 1 ml each o f the 
collected gentamicin sample, isopropanol (to prevent sedimentation) and ophthalaldehyde 
reagent, were mixed and left undisturbed for 20 minutes at room temperature [103]. The 
absorbance for the GS was measured at 333 nm using a Thermo Scientific NanoDrop 
2000c spectrophotometer.
Spectrophotometric determination o f NS was performed using copper chloride. 
This reagent was prepared by dissolving 12.5 mg copper chloride (sigma, MO, US) in 25 
ml o f a water-ethanol (4:1) mixture, then sonicating until a clear solution was formed 
[104], Collected sample (1 ml) was diluted with deionized water to 10 ml. To this sample, 
2 ml o f copper chloride solution was mixed and absorbance values were measured at 277 
nm [104],
3.1.8 Bacterial Cultures
Bacterial strain Escherichia coli and Pseudomonas aeruginosa were used in this 
study. Both were clinical grade strains kindly provided by Dr. Giomo, Department of 
Biological Sciences, Louisiana Tech University, LA. A single colony from each plate 
was picked using a sterile toothpick and was inoculated separately into 3 ml o f liquid 
broth (LB) medium. These cultures were incubated at 37°C for 24 hours with gentle 
rocking. From this medium, 50 pi was pipetted into LB-agar plates and spread using 
sterile glass beads. Discs o f 5 mm x 2 mm with different concentrations o f HNTs loaded 
with the drug were placed on the plates, then incubated at 37°C for 24 hours in an 
incubator. Inhibition zones were determined by measuring the diameter o f the inhibited 
area at three different points and averaged. The measured zones included the sample at
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the center. Three agar plates were tested for each sample. The principle objective o f this 
study was to determine the effectiveness o f antibiotics in HNTs incorporated into CPCs 
by means o f measuring the release profiles and determining the zone o f inhibition.
3.2 Results and Discussion
3.2.1 Mechanical Properties
3.2.1.1 Compression Strength
All formulations were subjected to compression testing. Five samples were tested 
for each formulation and the average was taken. Table 3-2 shows the compression 
strengths o f  all compositions. Most o f the samples washed o ff when they were immersed
in water for a day. Specimens 1 ,2 ,3 ,  4, and 7 were brittle and were broken before they
could be removed from the molds. Sample 11 was strong enough and showed great 
mechanical properties, but it was washed out in a day when immersed in water for testing 
the cohesive property (anti-washout property). None o f the samples which used sodium 
phosphate as a setting liquid could give a good anti-washout property. When 5% w/v 
chitosan lactate was used, the samples were hard, flexible and cohesive (Sample 18). 
Chitosan lactate, 10% w/v, was already a thick viscous liquid and hence higher 
concentrations o f it was not attempted.
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T able 3-2: Table showing the values o f peak load and compression pressure for each 
specimen.
























Sample 21 gave the largest compression strength. This composition, TTCP (1.46 
gm) and DCPA (0.54 gm) mixed in 10% w/v chitosan lactate, showed a cohesive nature 
and remained solid without disintegrating for several days when suspended in water. This 
formulation was used for all further experiments.
When HNTs were added to this formulation, an increase in compressive strength 
was recorded. This strengthening may be caused by crack-tip blunting [15], a process 
where a propagating crack is either deflected, cracked or stopped because o f solid particle 
obstruction. Different concentrations o f  HNTs in this formulation were subjected to 
compression testing, and the composition with 5% wt o f HNTs showed the highest 
compression resistance than the others. Figure 3-2 shows the stress-strain curves of 
individual CPC scaffolds with different concentrations o f  HNTs and Figure 3-3 shows 
the compression strengths o f CPCs with different HNT concentrations.
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The compressive stress-strain curves for all the constructs had increasing strain 
until breakage o f the sample. With the increasing stress, all the scaffolds showed initial 
fast increase followed by a slow decrease in strain. For all the control CPC constructs, the 
increasing strain curve was much smaller than HNT loaded CPCs. The stress-strain curve 
for 5% wt HNT CPC scaffolds had elongated, increasing the strain followed by a slow 
decrease. Upon further addition o f HNTs, the stress-strain curves showed a similar trend 
as that o f the control CPCs. This indicates that the compression strengths o f the CPCs 
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Figure 3-3: Compressive strengths o f CPC samples with different concentrations o f 
HNTs (mean ± SD, n = 5). Statistical significant differences are marked with * for 
p < 0.05 [105, 106],
A one-way ANOVA was conducted on these samples and a significant difference 
in the mean values among groups was seen. Using Tukey’s post hoc analysis, the highest 
average among the groups were identified as 5% wt HNT. Control CPC scaffolds had 
11.65 ± 2.24 MPa compressive strength, whereas CPCs with 5% wt HNTs had 16.5 ±
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0.95 MPa o f compressive strength. A 41% increase in strength upon the addition o f 5% 
wt HNTs were observed.
Upon further increasing the concentration o f HNTs, compressive strength 
decreased. Samples with 10% and 15% wt HNTs had 14.43 ± 1.64 MPa and 13.54 ± 1.67 
MPa o f compressive strength, respectively. Compressive strength o f both 10% and 15% 
wt HNT scaffolds was smaller than that o f the 5% wt HNT scaffolds but higher than that 
o f the controls. The reduced strength may be due to uneven distribution o f HNT particles 
or may be due to hindering the HA formation around their surfaces.
3.2.1.2 Flexural Strength
Figure 3-4 shows the flexural strength values o f CPCs scaffolds with and without 
HNTs added to them. The Control group (0% HNT) showed a strength o f 13.9 ± 2.5 
MPa, whereas 5% wt HNT samples had 17.1 ± 2.5 MPa o f flexural strength. Three 
samples for each batch were subjected to flexural testing. One-way ANOVA was 
conducted on these samples at 0.05 significance level. No significant difference among 
the mean values was observed. However, mean values o f the groups showed a 23.51% 
increase in flexural strength o f the samples upon addition o f  5% wt HNTs to the CPC 
samples. Similar to the compression strength values, further addition o f HNTs decreased 
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Figure 3-4: Flexural strengths o f CPC samples with different concentration o f HNTs 
(mean ± SD, n = 3). Statistical significant differences are marked with * for p < 0.05 
[105, 106],
3.2.2 Morphology o f CPC Scaffolds
The SEM images in Figure 3-5 show the surface morphology o f CPCs with and 
without HNTs. These scaffolds showed compact polygonal shaped microstructures o f 
varied sizes ranging from 5 pm to 15 pm. These highly aggregated microstructures had 
clearly visible interconnecting micropores. All cement formulations had rough surfaces. 
These rough surfaces may improve cell attachment and viability, making the scaffolds 
good substrates for cell conduction. Additionally, these micropores promote propagation 
o f cells within the scaffold.
Figure 3-5: SEM o f CPC scaffolds with different concentrations o f HNTs. A) 0%, B) 
5%, C) 10%, and D) 15% [105],
Upon further magnification, traces o f HNTs were found on the surface o f the 
scaffolds. Figure 3-6 shows the cluster o f HNTs on the CPC surface.
Figure 3-6: SEM showing cluster o f HNTs on the surface o f the CPC-HNT (5% wt) 
scaffolds. Image B was also used in Uday Jamm alam adaka’s dissertation [106].
51
3.2.3 XTT Assay
The viability o f human osteoblast cells on the surface o f  the CPC scaffolds was 
analyzed at days 3, 7 and 14 (Figure 3-7). Higher absorbance values indicate greater cell 
viability. Six wells o f each batch were tested and one-way ANOVA was conducted to 
analyze the significant changes among the groups. The mean values o f absorbance varied 
strongly with HNT concentration. On day 3, a 20.35% increase in absorbance values was 
observed for control CPC scaffolds when compared to wells containing only cells. On 
addition o f 5% HNTs to the CPC scaffolds, a 28.3% significant increase in absorbance 
value was noticed. For 10% and 15% HNTs, absorbance was 9.8% and 12.8% larger, 
respectively. However, when compared with control CPC scaffold (no HNTs added), 
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Figure 3-7: Cell viability assessed in human osteoblast culture on different CPC-HNT 
scaffolds (mean ± SD, n = 6). Statistical significant differences are marked with * for p 
< 0.05.
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On day 7, absorbance was larger for CPC scaffolds than for control wells. Wells 
containing 5% HNT samples showed 26.7% larger absorbance compared to CPC samples 
without HNTs. CPCs with 10% HNTs had the highest absorbance value.
On day 14, all wells containing CPC scaffolds showed higher absorbance values 
than the control wells and it was largest in scaffolds with 15% HNTs.
The absorbance values o f  the XTT assay reflects the mitochondrial activity o f the 
live cells. The results suggest that CPC scaffolds do not cause cyto-compatibility issues 
instead, they enhance the viability o f  the osteoblast cells. In addition, further increase in 
viability was seen upon addition o f  HNTs to the cement samples.
3.2.4 Drug Release Profile
An elution study was performed to estimate the amount o f drugs released over 
one week. A NanoDrop 2000c Spectrophotometer was used to measure GS absorbance at 
333 nm and NS at 277 nm. From the standard-graph curve, an equation was derived and 
was used to back calculate the amount o f drugs released. Figure A -l in the Appendix 
section shows the standard graph and linear equation used to back calculate the unknown 
samples concentration.
Figure 3-8 and Figure 3-9 shows the cumulative concentrations o f GS and NS 
released from HNTs and CPC-HNT scaffolds. Both scaffolds exhibit a burst release o f 
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Figure 3-8: Cumulative concentration o f GS released from HNTs and CPC-HNT 
scaffolds (mean ± SD, n = 3) [105].
Within 24 hours, 1.9 mg/ml o f drug was released from HNTs and 0.9 mg/ml from 
the CPC scaffolds. This initial outburst may be caused by release o f drug from the surface 
o f the HNTs. Only a small amount was released thereafter, but it was steady and 
extended. Once the release amount reached 0.94 mg/ml by 48 hours, the release rate 
decreased. Scaffolds could only release 0.05 mg/ ml from 48-120 hours, which was 
within the working concentration (4 fag/ml) o f  the drug.
54
0 20 40 60 80 100 120
Tim e (Hr)
Figure 3-9: Cumulative concentration o f NS released from HNTs and CPC-HNT 
scaffolds (mean ± SD, n = 3) [105],
The NS showed 1.04 mg/ml o f drug release from CPC scaffolds within 24 hours, 
whereas HNTs alone showed 2.39 mg/ml release. A cumulative concentration o f 1.12 
mg/ml was released from scaffolds for a total o f 120 hours. In all the samples, even after 
120 hours o f release, NS released from the constructs did not drop below the minimum 
inhibitory concentration (16 pg/ml). The graph in Figure A-2 o f the Appendix shows the 
standard curve and linear equation used to calculate the NS concentrations from the 
unknown samples.
The two graphs show that after 24 hours o f  release, elution decreased steadily. 
This decrease might be because the anti-infective agent inside the HNTs present on the 
surface o f  the scaffolds would have already emptied, and those HNTs entrapped inside 
the scaffold matrix might have not been exposed to sampling liquid. The antibiotic 
release might have continued if  the scaffolds were left to degrade.
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3.2.5 Bacterial Culture
Images in Figure 3-10 shows the inhibition zones for E. coli and P. aeruginosa 
incubated with CPC scaffolds loaded with different concentrations o f HNT-GS. Control 
samples (0% HNT) exhibited no inhibition zones. Images in Figure 3-10 (A-B) shows 
the inhibition diameters for E.coli and (C-D) for P. aeruginosa. Clearly delineated 
inhibition zones were seen in all the CPC-HNT-GS scaffolds. With the increase in 





Figure 3-10: Inhibition zones o f CPCs loaded with different concentrations o f  HNT-GS 
against E. coli (A-B) P. aeruginosa  (C-D).
Images in Figure 3-11 shows the inhibition zones o f CPC scaffolds loaded with 
different concentrations o f HNT-NS. Control sample (0% HNT) had no inhibition zones. 
Images in Figure 3-11 (A-B) shows the inhibition diameters for E.coli and (C-D) for P. 
aeruginosa. Similar to HNT-GS, clear delineating inhibition zones were seen in all the
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CPC-HNT-NS scaffolds. Inhibition diameter also increased with the increase in HNT 
concentration.
•  •
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Figure 3-11: Inhibition zones o f CPCs loaded with different concentrations o f HNT-NS 
against E. coli (A-B) and P. aeruginosa (C-D).
All these experiments were conducted in multiples o f three and one-way ANOVA 
was conducted at the significance level o f 0.05. Inhibition diameters were significantly 
different among the groups containing different concentrations o f HNT’s. Figure 3-12 
shows the Inhibition values o f different concentrations o f  CPC-HNT-GS against E.coli 
and P. aeruginosa. With the increase in HNT-GS concentration, zone o f inhibition 
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Figure 3-12: Inhibition diameters for E. coli and P. aeruginosa at different 
concentrations o f HNT-GS in CPC scaffolds (mean ± SD, n = 3).
Graph in Figure 3-13 shows the inhibition diameters for CPC scaffolds loaded 
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Figure 3-13: Inhibition diameters for E. coli and P. aeruginosa at different 
concentrations o f  HNT-NS in CPC scaffolds (mean ± SD, n = 3).
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One-way ANOVA conducted on these samples showed a significant difference 
among mean values at the significance level o f  0.05. With increase in HNT-NS 
concentration, zone o f  inhibition diameters also increased.
3.3 Conclusions and Future W ork
3.3.1 Conclusions
Calcium-phosphate cements have been investigated for several decades, and in 
this study, we have manipulated the formulations to yield enhanced mechanical 
properties and extended-drug release. Previous studies had shown that incorporation o f 
antibiotics directly into the cement yielded an improper drug release and reduced 
mechanical strength [107]. This reduced strength might be caused by a change in the 
crystal’s structure or the dissolution o f antibiotics to leave pores [14]. The cement must 
be formulated such that it can give an antibiotic property to the cement without 
compromising the mechanical properties. This result was achieved by the addition o f 
HNTs in the CPC mixture. HNTs worked here both as the drug carrier and mechanical 
property enhancer.
In this study, addition o f HNTs to the cement mixture increased compression and 
flexural strengths. SEM imaging reveals that the CPC scaffolds have rough surface with 
embedded micro-pores. This surface roughness might increas the cell attachment and the 
micro-pores aid in propagation o f  cells within the scaffold making the cement 
osteoconductive.
Cell viability assay on human osteoblast cells with CPC-HNT scaffolds showed 
no deleterious effects on the cells, proving that formulated CPC scaffolds do not cause 
harm in vivo. In addition, an increased viability was recorded with the addition o f  HNTs.
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As HNTs are hollow and have high length/diameter ratio, they naturally have the 
ability to be loaded with substances and to yield a prolonged release. Because o f this 
property, when HNTs loaded with antibiotics are mixed with the CPCs, they gave 
extended-release profiles. As the loaded HNTs are also present inside the scaffolds, we 
believe drug release would continue for several days when cement starts degrading to 
form bone. Zone o f inhibition studies show that the scaffolds were able to inhibit 
bacterial growth and provide an anti-infective field at the site o f implantation.
3.3.2 Future Work
In this study, only antibiotics were used for testing the anti-microbial properties o f 
the CPCs. Multiple anti-infective agents such as anti-viral and anti-fungal can also be 
loaded into HNTs for synergistic and wide range anti-microbial properties. Bone growth 
hormones such as BMP-2, BMP-6 and others can also be loaded in the HNTs and can be 
used to promote bone healing along with providing an anti-infective field around it.
The present in vitro study showed that CPC scaffolds are osteoconductive and can 
be considered as a potential implant material. These scaffolds can be tested in vivo in 
mice, rats or other suitable specimens.
CHAPTER 4
3D PRINTING ANTIBIOTIC AND CHEMOTHERAPEUTIC 
LOADED BIODEGRADABLE SCAFFOLDS
4.1 Introduction
Currently used implants include metallic rods, pins, plates, screws, and acrylic 
cements which support the injured bone and hold it in position. Although these 
traditionally used implants have been proved clinically efficacious, they stay at the site o f 
implantation permanently, need secondary revisions and surgical removal upon healing 
[5]. Metal implants are often removed to prevent or correct complications such as 
accumulation o f metals in tissues [108], cessation o f tissue growth in and around the 
implant [109], trauma, and implant migration [110]. Most o f these implants are bulk 
manufactured, do not account for individual differences, and must often be machined 
according to the patient’s requirements. This approach could increase both operative time 
and cost.
Additionally, the risk o f microbial infection, especially for open-fractured bone 
fixation and joint-revision surgeries, is always high [111]. Sources o f the infection 
include bacteria on the patient’s skin, microbes already residing in the patient’s body, 
surgical equipment used, environment o f the operating room, and clothing worn by 
medical and paramedical staff [112], Current implant technology could be improved to 
make the implants more biocompatible and anti-microbial in nature.
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Recent advances in biomaterials for medical use have offered a promising 
alternative to these permanent implants. Biodegradable implants offer economical and 
clinical advantages over metal implants [113]. They can provide a necessary amount o f 
mechanical strength, and degrade at a pace similar to new tissue formation. These 
implants can transfer the load safely to the newly formed bone and eliminating the need 
for revision/removal surgery [114]. Permanent implants including metals (titanium 
alloys, stainless steel, cobalt-chromium alloy), ceramics, acrylic cements and rigid 
synthetic plastics (polyethylene and polyurethane) are often cited for stress shielding due 
to their rigid nature [115] and interfere with the imaging techniques during post-operative 
analysis.
In the present work, methods to introduce anti-infective and chemotherapeutic 
properties to the filaments used in 3D printing were fabricated. Different constructs 
resembling the medical implants currently used, such as beads and catheters, were 3D 
printed. Changes in compression and flexural strengths with print orientation, infill ratio 
and drug addition were studied. Surface morphology was studied using SEM. Bacterial 
culture and osteosarcoma cell culture were performed to test the bioactivity o f the 
constructs.
The basic foundation for this work was a part o f a group project with Jeffery 
Weisman. Data obtained from SEM imaging, bacterial inhibition cultures and XTT assay 
were shared with Jeffery Weisman.
4.2 Materials
All plastic wares such as 2 ml Eppendorf tubes, 96 well plates, and pipettes were 
purchased from Mid Scientific, St. Louis, MO. Dulbecco’s Phosphate Buffered Saline
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(DPBS), Dulbecco’s Modified Eagle’s Medium (DMEM), Fetal Bovine Serum (FBS), 
and penicillin-streptomycin-amphotericin (PSA) antibiotics were purchased from Life 
Technologies, Grand Island, NY. For bacterial culture, 100 mm Mueller Hinton agar 
plates were purchased from Fischer Scientific (Hampton, NH) and Escherichia coli 
ATCC 1 1775 Vitroids 1000 CFU were from Sigma Aldrich (St. Louis, MO). 
Methotrexate (MTX), Gentamicin Sulfate (GS), tobramycin and nitrofurantoin were 
ordered from Sigma Aldrich (St. Louis, MO). PLA pellets used for extruding filaments 
were obtained from Push Plastic (Springdale, AR), KJLC 705 silicone oil used for 
coating pellets was purchased from Kurt J. Lesker Company (Jefferson Hills, PA). 
ExtrusionBot filament extruder was bought from ExtrusionBot, LLC (Pheonix, AZ), 
MakerBot replicator 3D printers were purchased from MakerBot (Brooklyn, NY), 
Nanodrop used for spectrophotometry was from Thermo Scientific (Wilmington, DE), 
and the Vulcan A550 series benchtop Muffle furnaces from Thomas Scientific 
(Swedesboro, NJ) was used for heating biomaterials. OPTA reagent, isopropyl alcohol 
and sodium tetra borate were ordered from Sigma Aldrich (St. Louis, MO). For modeling 
3D constructs, Solidworks 2015 was used. For 3D scanning o f objects, A Roland 
Corporation LP-250 desktop 3D scanner (Osaka, Japan) was used.
4.2.1 Bioplastics
PLA is an aliphatic polyester, approved by the US Food and Drug Administration 
(FDA) for direct contact with biological fluids [116]. Pellets with diameters 3-5 mm were 
ordered from Push Plastic, Springdale, AR. Figure 4-1 shows the chemical structure o f 
PLA and a bag o f pellets.
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Figure 4-1 : A bag o f PLA pellets and its molecular structure.
In this study, these PLA pellets were used for extruding filaments and 3D printing 
constructs with drugs loaded.
4.2.2 Computer Modeling
The Solidworks 2015 was used to desgin all the constructs required for testing the 
properties o f  printed scaffolds. Figure 4-2 shows the interface o f the program with a stent 
design.
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Figure 4-2: Solidworks 2015 interface showing a design o f the stent.
All the constructs designed in this CAD program were saved in STL format in 
order to make these files readily available for the 3D printer to print.
4.2.3 Filament Extruder
For extruding filaments out o f  coated PLA pellets, a first generation ExtrusionBot 
filament extruder, shown in Figure 4-3A, was used.
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Figure 4-3: A) ExtrusionBot filament extruder, B) Piston based auger system inside 
ExtrusionBot.
This device works on a principle o f piston based auger mechanism. Plastic pellets 
were fed into the hopper at the top o f  the device. The piston pushes the pellets down to 
the metallic die through heated element as shown in Figure 4-3B. Sensors arranged 
around this heating element regulate the temperature. Dies o f different diameter at the 
bottom o f the device can be used to customize the thickness o f the extruded filament. 
4.2.4 3D Printer
MakerBot 1st generation and MakerBot 5th generation, shown in Figure 4-4A and 
B, respectively, were used to print the extruded filaments.
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Figure 4-4: A) MakerBot Replicator 1st Generation, B) MakerBot Replicator 5th 
Generation.
These printers work on FDM principle. These devices provide a three-axis 
movement consisting o f two simultaneous translational movements o f a printer-head 
along the x and y axes and an additional movement by the printer platform along the z 
axis. Inside the printer-head lies a metallic barrel where filaments are electrically heated 
and extruded under computer control through a nozzle. Figure 4-5 shows the interface of 
the Makerware software and its customizable settings.
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Figure 4-5: Screenshot o f Makerware software showing customizable settings.
The MakerBot replicator 1st Generation has two printer heads, whereas the 5th 
Generation has only one head attached. Both o f these require filament o f 1.75 mm in 
diameter to print objects. They are designed to print PLA and ABS plastics. The 
temperature they used to print is typically 220°C for PLA and 235°C for ABS. As with 
the temperature, the resolution o f the object to be printed can also be customized within 
the range o f  50-400 microns. The percentage o f  infill for the constructs can also be 
modified.
4.2.5 3D Scanner
A Roland LP-250 desktop 3D scanner was used (Figure 4-6) to scan 3D objects.
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Figure 4-6: Roland LP-250 desktop 3D scanner.
This scanner uses a software called PICZA to convert the scanned data into a STL 
file for either CAD program or a 3D printer to read. An object is placed on the rotating 
bed o f  the scanner and it rotates the object 360°. At the same time, a laser beam travels 
vertically upwards collecting the data from the object into a digital file. For complex 
shaped objects, it scans multiple times and merges all the scans to generate an accurate 
representation.
4.3 Extruding Drug Loaded Filaments
Loading drugs into biopolymers and engineering them into a suitable form for 
printing into constructs was a challenge. Added to that, PLA is not available
commercially as fine powder. It is obtained easily in the form o f pellets o f  different 
shapes and sizes. Since these are plastic, grinding them into fine powder was a difficult 
task. Freeze fracturing pellets into powder is an expensive and difficult option. We have 
come up with the following method to coat pellets with the drugs and these coated pellets 
were extruded into filaments o f  1.75 mm in diameter for 3D printing constructs.
4.3.1 Coating Pellets with Drugs
To enable an even dispersion o f drugs on the surface o f the commercially 
available PLA pellets, an oil coating method was used. Figure 4-7 shows an illustration 
o f oil coating method. To surface coat pellets, KJL 705 silicone oil was chosen because 
o f its thermal stability at extrusion temperatures (170-180°C). The method required 20 
gm batch o f  pellets, to which was added 15 pL o f  silicone oil and then vortexed to make 
sure all the pellets were evenly and completely coated. Once vortexed, the pellets were 
transferred to another container in order to avoid loss o f drug powder due to sticking to 
the surface o f the oil coated mixing container. After switching containers, a calculated 
amount o f a drug in powdered form (gentamicin sulfate for anti-infective filament and 
methotrexate for chemotherapeutic filament) was added and vortexed again.
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Figure 4-7: The process o f coating PLA pellets with drugs. A) Coating oil is added, B) 
Tube is vortexed, C) Pellets are transferred to a new tube, D) Drug is added, E) Tube is 
vortexed, F) Coated pellets are removed [117].
Using this method, l% w t GS-PLA pellets and l% w t MTX-PLA pellets were 
made as shown in F igure 4-8. To make sure o f uniform distribution, drugs were 
grounded with mortar and pestle prior to the addition.
Figure 4-8: Drug coated PLA pellets. A-B) Control PLA, C-D) 1% wt GS coated 
pellets, E-F) 1% wt MTX coated pellets [117].
In addition to this, other methods such as direct mixing o f  drugs during extrusion 
and atomizer based coating were tried. These methods resulted in non-uniform coating o f 
drugs.
4.3.2 Filament Extrusion
For extruding these coated pellets, an ExtrusionBot filament extruder was used. 
Since the 3D printer used requires a filament with a diameter o f 1.75 mm to print, we 
have used metal die o f the same diameter to extrude the filament. Each 20 gm o f GS and
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MTX coated PLA pellets were extruded at 170°C maintaining the outcoming filament 
diameter as 1.75 mm. We also tried extruding below 170°C, but that slowed down the 
extrusion speed and resulted in thicker filament which could not be used for printing. At 
higher temperatures, PLA melts down completely and flows through the metal die 
causing thermal runaway. Since this equipment works on piston based auger system, back 
pressure was necessary. Small batches o f pellets could not provide sufficient pressure and 
stayed inside the extruder for a longer time period, resulting in excessive heating o f  the 
pellets and thin filament extrusion. For PLA, 20 gm batches extruding at 170°C were 
optimum conditions for getting a filament with a 1.75 mm diameter.
4.4 Optimization o f 3D Printing Parameters
A 3D printer based on FDM is a very delicately balanced machine. If filament 
temperature, speed o f  extrusion and speed o f the printer-head are not balanced together, it 
does not yield constructs o f the required shape. Also, an optimized 3D printing process 
involves complex integration between hardware, software and material properties. 
Preliminary trials revealed that the printer head temperature and filament feed rate have a 
direct influence on the material flow for the fabrication o f the scaffolds. For this reason, 
optimization o f printing parameters for PLA was focused mostly on printer-head 
temperature and filament feed rate. We first determined the minimum temperature o f  the 
printer-head that could print PLA, and then we adjusted the filament extruding rate 
accordingly.
On the MakerBot l sl generation 3D printer, PLA could print at a lowest 
temperature o f 215°C, and to compensate this, we had to decrease the printer-head speed 
from a default 40 mm/s to 10 mm/s and increase the filament feed rate from a default 18
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mm/s to 23 mm/s. The workable range o f parameter for a 1.75 mm diameter PLA 
filament was determined to be a 215°C printing temperature, 20-23 mm/s o f filament 
feed rate and 12-8 mm/s printer-head speed.
4.5 Scaffold Design and Fabrication
All 3D CAD models were designed using Solidworks 2015 and Blender software. 
PLA scaffolds were fabricated for two sets o f experiments. The first set o f experiments 
was to study the effect o f infill and printing axis on the mechanical properties o f the 
scaffolds. The second set was to investigate the printed construct’s bioactivity.
For the first set, compression cylinders with dimensions 6 x 1 2  mm and dumb-bell 
(dog bone) shaped bars o f 75 x 1 0 x 4  mm were designed in solidworks CAD software. 
These models were sliced using replicatorG software and exported as .stl and .x3g 
formats for the printer to read. A honeycomb pattern o f infill was used for all the 
constructs. To determine the effect on physical properties, scaffolds with different infill 
ratios 25%, 50%, 75%, and 100% were printed. Scaffolds were printed along different x, 
y and z axes, to check if  the printing axis has any effects on mechanical strength.
For the second set, antibiotic loaded discs o f 5 x 1 mm were printed for bacterial 
studies and chemotherapeutic discs o f the same dimensions for osteosarcoma culture 
were printed. To replicate the currently used bone cement implants, beads o f 6 mm 
diameter and 14 French catheters o f  30 mm in length were also printed and tested for 
drug release and bacterial cultures. All the fabrication conditions were maintained the 
same as the first experimental set, except that these scaffolds were all printed at a default 
10% infill.
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4.6 Thermal Decomposition Testing
For extruding PLA filaments from pellets, they were run through the extruder at 
170°C and for printing these extruded filaments, the printer-head needs a temperature o f 
220°C. To test the thermal stability, small batches o f  drugs (1 mg each) were heated in a 
Vulcan oven for five minutes at different temperatures ( 175°C, 195°C, 205°C, 215°C, 
225°C, and 235°C) and were subjected to bioactivity testing. For antibiotics, standard 
muller hinton agar plates were used and for chemotherapeutics, a XTT assay on an 
osteosarcoma cell line was performed. All these samples were investigated in triplicate.
4.7 Scaffold Characterization
4.7.1 Morphology
For external morphology studies, the S4800 Field Emission SEM, HITACHI 
(Schaumburg, IL) at different magnifications was used. Extruded filaments, 3D printed 
constructs (discs, beads, and catheters) and controls were subjected to SEM.
4.7.2 Mechanical Properties
An ideal implant should have a proper balance o f mechanical and physical 
properties. The optimization o f properties such as hardness, elasticity, yield stress, 
wearability and time o f  degradation completely depends on type and functionality o f the 
implant [118]. For example, sutures, catheters, surgical meshes and other smaller 
implants such as cochlear or vascular grafts do not need strong mechanical properties, 
whereas dental and orthopedic implants need higher load bearing capabilities. Due to this, 
we aim to customize the properties o f the implants by changing the printing parameters to 
make them available for wide applications.
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Scaffolds with different infill ratios, different orientations and with drugs loaded, 
as shown in Figure 4-9 and Figure 4-10, were printed. These constructs were subject to 
compression and flexural testing.
0% 10% 25%
- ' * *
5 0
7 100%
X axis Y axu
Z axis
Figure 4-9: Printing PLA constructs with A) Different Infill ratios, B) Different 
Orientations.
Figure 4-10: Printing PLA constructs. A) MTX-PLA mechanical testing samples,
B) GS-PLA mechanical testing samples.
For testing the mechanical properties, both compression and flexural testing was 
performed using an Admet 2600 Dual Column Bench Top Universal Testing Machine.
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For data acquisition and analysis, MTESTQuattro software was used and this was 
company equipped along with the instrument. For both tests, ASTM F451-99a 
(characterization o f mechanical properties o f  bioresorbable scaffolds) guidelines were 
followed. Load capacity o f 1 KN was laid on the scaffolds at a rate o f 1 mm/min. The 
flexural testing three-point bending method, as shown in Figure 4-11, was followed.
Figure 4-11: Image showing three point bend testing performed on PLA samples.
4.7.3 Drug Release Profile
For drug elution profiles, a NANODROP 2000 UV-Visible Spectrophotometer 
from Thermo Scientific was used. Drug loaded extruded filaments (1 cm length), beads, 
catheters and control PMMA beads were subjected to this study. Simulated Body Fluid 
(SBF) was used to collect the samples from the constructs periodically. The time intervals 
for collecting samples were 1 minute, 2 minutes, 5 minutes, 10 minutes, 20 minutes, 40
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minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, and then daily for a week. For MTX, 
direct detection at 300 nm was performed. Since GS could not be directly detected, 
indirect determination using OPTA reagent was done. Equal volumes o f collected 
sample, isopropyl alcohol and OPTA reagent were added, and this mixture was analyzed 
using spectrophotometer at 330 nm. SBF was used as a blank for all these tests. Measured 
quantities o f drugs were used to draw standard graphs and from these absorbance values, 
the amount o f  drug eluted in the collected samples were back calculated. The graphs in 
Error! Reference source not found, and Error! Reference source not found, o f the 
Appendix section were used as standards for calculating concentrations o f GS and MTX 
from unknowns, respectively.
4.7.4 Bacterial Cultures
To assess the bacterial activity o f GS, zone o f inhibition studies were conducted 
on standard Muller Hinton Agar Plates using E.coli and S. aureus. For repeatability, 
vitroids o f these two bacterial strains were ordered from Sigma Aldrich and used. These 
vitroids were rehydrated and inoculated into agar plates as per the procedures suggested 
in the manual. Plain PLA pellets, coated PLA pellets, extruded PLA filament, GS loaded 
PLA filament, beads and constructs were tested. To make sure there was no 
contamination among agar plates, a blank plate was cultured. An agar plate with just the 
bacteria acting as negative control and another with standard GS disc as positive control 
were also cultured. Under aseptic conditions, samples were inoculated along with the 
bacteria in the plates and incubated at 37°C for 24 hours. The diameter o f inhibition 
zones was measured at three different points including the samples at the center o f the 
zone and averaged.
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4.7.5 Osteosarcoma Cell Culture
To test the chemotherapeutic activity o f MTX, osteosarcoma cell line (CRL 2836) 
bought from ATCC (Manassas, VA) was used. These cells were incubated in complete 
DMEM having 10% FBS and 1% PSA at 37°C until they were confluent. These 
confluent cultures were passaged and seeded on to 96 well plates containing test 
scaffolds. A XTT assay was conducted on the third day o f the experiment.
For this assay, control filaments, MTX coated filaments, control 3D printed discs 
and MTX PLA 3D printed discs were cultured along with the cells in 96 well plates. The 
XTT assay procedure was conducted as per the manufacturer’s protocol. After aspiration 
o f the media, each well was added with 100 pL buffer and 20 pL XTT dye. These plates 
were then incubated for 4 hours and photometric absorption o f  each well was measured 
using Phenix LT-4000 absorbance microplate reader at 450 and 690 nm. The 
manufacturer’s protocol followed for this assay is mentioned in Appendix B.
4.7.6 Statistics
All mechanical testing samples were studied in multiples o f five to make sure the 
results are consistent, reproducible and not altered by random events. For comparing the 
means o f the strengths among the different groups, the one-way ANOVA test was 
performed at a significance level o f 0.05. Post hoc analysis was used to calculate the 
highest average among the groups. Standard deviation was calculated and used in the 
graphs as error bars.
For drug elution studies and bacterial cultures, three samples o f each batch were 
tested. Standard deviation o f the means was calculated and used as error bars in the 
graph.
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4.8 Results and Discussion
PLA pellets were successfully coated with drugs GS and MTX using oil coating 
methods. Optimization o f the amount o f silicone oil used to coat the pellets was 
challenging. Excess oil resulted in clumping o f pellets together and clogging the extruder 
during extrusion process. However, low amounts o f oil would only allow pellets to hold 
small proportions o f drugs on to their surface. For a batch o f 20 gm pellets, 10-15 pL of 
silicone oil was found to yield the best results. Filaments o f 1.75 mm diameter were 
successfully extruded from coated pellets using the ExtrusionBot extruder at 170°C. 
These filaments were used in MakerBot 3D printers and scaffolds were printed. Figure 
4-12 shows images o f scaffolds 3D printed using custom extruded bioactive filaments.
Figure 4-12: A) 1% wt GS-PLA catheters, B) 1% wt MTX-PLA catheter, compression 
cylinder and bead, C) 1% wt GS-PLA beads, D) 1% wt MTX-PLA beads.
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4.8.1 Scanning Electron Microscopy (SEM)
SEM was used for studying the surface morphology o f the coated pellets, 
extruded filaments and printed scaffolds. Figure 4-13 shows images o f pellets coated 
with drugs. GS particles were round in shape and the spheres had a wide range o f 
diameters (from 1 pm to more than 50 pm), whereas MTX particles were polygonal in 
shape and are varied in sizes.
1.00 mm
Figure 4-13: SEM o f A) Control pellet, B) GS powder, C) 1% wt GS-PLA pellet,
D) MTX pellet, E) 1% wt MTX-PLA pellet. Images D and E were also used in Jeffery 
W eism an’s dissertation [117, 119].
Extruded filaments comprise a cylindrical shape with a 1.75 mm diameter. The 
SEM images in Figure 4-14 show the surface morphology o f Control, GS and MTX 
filaments.
Figure 4-14: SEM o f A) Control filament, B) 1% wt GS-PLA filament, C) 5% wt GS- 
PLA filament, D) 1% wt MTX-PLA filament, E-F) MTX crystals on the surface o f 
filament at different levels o f magnification. Images D and F were also used in Jeffery 
W eisman’s dissertation [117, 119].
The images o f control and l% w t GS filaments does not show much difference 
between them. However, increasing the concentration o f GS showed distortion on the 
surface o f the filament as shown in Figure 4-14 C. This might be the reason for 5% wt 
GS filaments to be brittle and not print smoothly. The surface o f  the 1% wt MTX 
filaments were also smooth, cylindrical in shape and deep yellow in color. On further 
magnification, trace amounts o f MTX crystals were seen on the surface o f the 1 % wt 
MTX filament.
SEM images in Figure 4-15 shows the surface morphology o f 3D fabricated 
beads and catheters.
Figure 4-15: SEM o f A) 1% wt MTX-PLA bead, B) MTX powder on surface o f the 
bead, C) 1 % wt MTX-PLA catheter, D) 1 % wt GS-PLA catheter, E) GS on the surface 
o f the catheter, F) 1% wt GS-PLA bead. Images D-F were also used in Jeffery 
W eism an’s dissertation [119],
These images show the layers o f filament being deposited on top o f each other 
like a stack o f rope. These filament layers comprise a cylindrical shape with 300 pm in 
diameter and good sintering between the layers. The image in Figure 4-15 (A) shows the 
sintered layers o f  the 1% wt MTX-PLA bead, on increased magnification MTX particles 
can be seen on the surface. Similarly, the image in Figure 4-15 (D) shows the surface o f 
the sintered layers o f 1% wt GS-PLA catheter and upon further magnification individual 
GS particles can be seen on its surface in Figure 4-15 (E).
4.8.2 Mechanical Properties
The flexural strengths o f different 3D printed control PLA scaffolds with different 
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Figure 4-16: Flexural strengths o f PLA constructs printed in different infill ratios and 
orientations (mean ± SD, n = 5). Statistical significant differences are marked with * for 
p < 0.05.
There was no significant difference seen between 25%, 50% and 75% infill 
samples and the 100% infill samples had the highest flexural strengths. Among different 
orientations, samples printed along the Y axis showed high flexural strengths. Samples 
printed along the X axis had 8% less and along the Z axis had 26% less flexural strengths 
when compared to Y axis prints. This might be due to the alignment o f filament layers 
along the length o f  the specimens, whereas in other orientations, filaments were sintered 
with each other perpendicular to the length o f  the specimen.
The graph in Figure 4-17 shows the flexural strengths o f  PLA samples printed 
with and without drugs. Extruded control PLA prints had mean flexural strength o f  78 
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Figure 4-17: Flexural strengths o f control, GS and MTX-PLA constructs, (mean ± SD, 
n = 5). Statistical significant differences are marked with * for p < 0.05.
Unlike flexural strengths, compression strengths o f  the samples printed with 
different infill ratios showed a significant difference in their mean values. Graph in 
Figure 4-18 shows the stress-strain curves o f PLA constructs and Figure 4-19 shows the 
compression strengths o f samples printed with different infill ratios and in various 
orientations. Samples printed at 100% infill ratio showed the highest compression 
resistance among other infills. There was no significant difference in means o f 
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Figure 4-19: Compression strengths o f PLA constructs printed at different infill ratios 
and orientations (mean ± SD, n = 5). Statistical significant differences are marked with * 
for p < 0.05.
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The graph in Figure 4-20 shows the compression strengths o f PLA samples with 
different drugs. The control PLA scaffolds had compression pressure o f  67.66 MPa. 
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Figure 4-20: Compression strengths o f  control, GS and MTX-PLA constructs (mean ± 
SD, n = 5). Statistical significant differences are marked with * for p < 0.05.
4.8.3 Drug Release Profiles
The graph in Figure 4-21 shows the cumulative concentration o f  drug released 
from the 3D printed PLA-GS scaffolds and PMMA bead at different intervals o f time. 
The cumulative concentration o f drugs released were plotted with respect to time. As it 
can be seen, all scaffolds showed an initial outburst during the first few hours followed 
by a steady release. This initial burst may be due to rapid diffusion o f drug from the 
external surface o f  the scaffolds. The following steady release may be attributed to
8 8
diffusion o f drug from the scaffold matrix. The active ingredient dissolves into the liquid 
within the scaffold matrix and then diffuses into the bulk medium.
The amount o f GS released from the 3D printed bead was less when compared to 
a GS loaded PMMA bead. Even after a week, all the scaffolds were still releasing GS 













Figure 4-21: Cumulative concentration o f GS eluted from 3D printed PLA bead, 
catheter and hand mold PMMA bead (mean ± SD, n = 3).
For MTX release study, 3D printed bead and catheter along with PMMA bead 
was used. Among these samples, only 3D printed catheter and PMMA bead were eluting 
drug within the detectable range. This might be due to hydrophobic nature o f the drug or 
may be drug-polymer interactions. Higher concentrations (2.5% wt and 5% wt) o f  MTX 
filaments were extruded, catheters were 3D printed and used for elution. Graphs in 
Figure 4-22 and Figure 4-23 show the cumulative drug elution from different 
concentrations o f PLA-MTX catheters and PLA-PMMA bead.
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Figure 4-22: Cumulative concentration o f MTX released from 3D printed PLA 
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Figure 4-23: Cumulative concentration o f  MTX eluted from PMMA bead (mean ± SD, 
n = 3).
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The release profile o f MTX from PMMA was similar to GS-PMMA elution. At 
the end o f 120 hours, 34.57 pg/ml (cumulative concentration) o f drug was released from 
the PMMA bead, whereas 2.5% and 5% MTX 3D printed catheters could elute only 5 
pg/ml and 12.5 pg/ml (cumulative concentration) o f MTX, respectively.
4.8.4 Bacterial Culture
For a PLA thermoplastic to be extruded and 3D printed, it has to undergo heating 
process up to 170°C for filament extruding and 215°C for 3D printing. So studying the 
thermal degradation o f drugs used is necessary. GS batches o f each 100 mg were heated 
at different temperatures for five minutes in a Vulcan oven and 1 mg o f it is incubated 
along with the E. coli in agar plates. All these experiments were performed in multiples 
o f  three. F igure 4-24 shows the zones o f inhibition for GS heated at different 
temperatures.
F igure 4-24: Zone o f  Inhibitions for GS heated at different temperatures on E. coli 
cultures A) Controlled uncooked, B) 175°C, C) 195°C, D) 205°C, E) 215°C, F) 225°C 
and G) 235°C.
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The average zone o f inhibition for control GS was 37.39 mm and for GS heated at 
175°C was 36.62 mm. ANOVA analysis showed no significant difference between the 
two means. Figure 4-25 shows the mean zone o f inhibition values for GS heated at 
different temperatures for five minutes. A total o f 11.07% reduction in inhibition 
diameter for GS heated at 195°C when compared with control. Similar inhibitions were 
recorded for 195°C and 205°C heated GS groups. Makerbot 3D printer used temperature 
o f 215°C for printing PLA filaments. For GS group, heated at 215°C, at total o f 21.03% 
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Figure 4-25: Zone o f  inhibition for GS heated at different temperatures (mean ± SD, n 
3).
The images in Figure 4-26 shows the zone o f  inhibition for GS coated pellets, 
filaments and 3D printed discs. PLA pellets coated with 2.5% wt GS showed an average 
o f  29.04 mm diameter zone o f inhibition. Control PLA and PMMA filaments, as shown
in Figure 4-26 A, did not show any kill zones. Clear demarcating inhibition zones were
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seen for PLA and PMMA filaments loaded with GS. The mean zone o f inhibition for 
2.5% wt PLA-GS was 23.13 mm and 2.5% wt PMMA-GS was 22.58 mm. ANOVA 
analysis showed no significant difference between the two means.
Similarly, the mean zone o f inhibition diameters o f 3D printed discs and hand 
mold PMMA discs were 21.36 mm and 22.02 mm, respectively. ANOVA analysis 
showed no significant difference in the mean values o f both groups.
20 rnm
Figure 4-26: Zone o f  Inhibitions for E. coli cultures A) PLA-GS pellet, B) PLA and 
PMMA filaments with and without GS, C) PLA and PMMA discs with and without GS. 
Image A was also used in Jeffery W eism an’s dissertation.
The 3D printed beads and catheters also showed a clear demarcating zone o f 
inhibitions. Figure 4-27 shows the inhibition zones for PLA-GS beads and catheters
incubated with E. coli.
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Figure 4-27: Zone o f Inhibitions for PLA-GS bead and catheter on E. coli.
The same method was followed for fabricating tobramycin-PLA constructs. The 
tobramycin laden discs showed no zones o f inhibition as shown in Figure 4-28. 
However, clear zones were seen for PMMA-tobramycin discs. This may be due to low 
melting o f  tobramycin or its interactions with the polymer.
Figure 4-28: A) 1 wt% tobramycin PMMA disc, B) 1 wt% tobramycin PLA disc, 
C) 2.5 wt% tobramycin PMMA disc, D) 2.5 wt% tobramycin PLA disc [119, 117].
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4.8.5 Osteosarcoma Cell Culture
Since bioactive compounds undergo fabrication process involving temperatures 
up to 215°C, thermal stability study was necessary. Figure 4-29 shows the absorbance 
values o f XTT assay performed on osteosarcoma cells at day one. It is to be noted that 
these absorbance values correspond to the growth o f  the cells. The absorbance o f the well 
was directly proportional to the susceptibility o f the cells. Five wells o f each sample was 
used for the assay. Both control MTX and heated MTX showed significant differences in 
absorbance values when compared to control cells. A total o f a 65.41% reduction in 
absorbance values was recorded for groups containing MTX. ANOVA was performed 
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Figure 4-29: Absorbance values o f  XTT assay performed on osteosarcoma cells with 
different MTX groups at day one (mean ± SD, n = 3).
MTX enhanced PLA filaments were also tested on 96 well plates. In this study, 
eight test groups with six wells each were used: control cells, control MTX, heated MTX,
95
control PLA pellet, oil coated PLA pellet, MTX coated PLA pellet, control PLA filament, 
MTX PLA filament. An enhanced cell growth was recorded in groups lacking MTX as 
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Figure 4-30: Absorbance values o f XTT assay performed on osteosarcoma cells with 
different PLA scaffolds enhanced with MTX (mean ± SD, n = 6) [ 117],
PLA pellets coated with silicon oil and uncoated PLA pellets showed no statistical 
differences in their mean absorbance values when compared with control cells. There was 
no significant difference between PLA filament and control cell groups either. Wells 
containing MTX pellets and MTX filaments showed a significant decrease in cell 
proliferation when compared to both the control well and PLA filament control well. A 
total o f 43.15% and 31.72% reduction in absorbance values was shown in MTX pellets 
and MTX filament groups. ANOVA analysis confirms statistical differences between 
XTT viability assays o f  the methotrexate enhanced filament/pellet and the respective 
control groups.
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4.8.6 Scanning Bone Defects
In bone diseases such as osteomyelitis and osteosarcoma, affected regions o f the 
bone will be debrided out by the surgeon and those defects could be refilled with drug 
eluting spacers. Using CT scans o f the bone, defective parts can be identified and spacers 
can be 3D printed with accurate dimensions before the physician could even start surgery. 
This process will help in reducing the total duration o f time taken for the surgery. In this 
part o f  the study, a cow femur was used to model this concept. Irregular and standard 6 
mm defects were made using drill press machine on the femur bone as shown in Figure 
4-31.
Figure 4-31: A) Cow femur with irregular bone defect, B) Cow femur with 6 mm 
diameter defects 1 wt% [119].
Using the Roland Desktop 3D scanner, the bone was scanned and defective 
regions were manually processed using blender and solidworks software. These 
processed bone defects were saved as STL files and 3D printed using customized drug
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loaded filaments. Figure 4-32 shows the images o f  a 3D scan o f the bone, processed 
bone plugs and 3D printed bone plugs.
ID mm
Figure 4-32: A) 3D raw scan o f cow femur showing 360 degrees o f defect in 180 
degree image, B) CAD rendering o f  negative 6 mm diameter defect, C) CAD rendering 
o f negative o f  irregular defect, D) 1 wt% gentamicin print o f irregular defect with 
control, E) MTX print o f  irregular defect. Images in A-D were also used in Jeffery 
W eism an’s Dissertation.
Control PLA, GS-PLA and MTX-PLA bone defects were printed and test fitted 
over the defects. 3D fabricated bone plugs were found to fit the defects precisely. Images 
in Figure 4-33 shows bone plugs fitted into the bone defects.
Figure 4-33: A) Femur with irregular defect, B) Femur with control-PLA fitted insert, 
C) Femur with GS-PLA fitted insert [119].
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4.9 Conclusion
Recent advances in additive manufacturing and biomaterials provide the potential 
to 3D fabricate custom constructs for personalized medicine with targeted drug delivery. 
A novel method for coating biodegradable PLA pellets with bioactive compounds and 
extruding them as filaments o f required diameter was developed. These extruded 
filaments were successfully printed into constructs o f required shapes such as beads, 
catheters and others. Antibiotic coated pellets, extruded filaments and 3D printed beads 
were tested in bacterial cultures to confirm their anti-infective property. The results 
indicated that the GS loaded constructs retained their bioactivity and provided clear anti- 
infective regions around them. Similarly, XTT assay performed on osteosarcoma cells 
showed significant reduction in cell growth among groups containing MTX filaments and 
printed discs when compared to control groups.
SEM images showed coating o f drugs on the surface o f the pellets. These images 
also showed the presence o f  bioactive compounds on the surfaces o f the extruded 
filaments and 3D printed constructs. Comparison testing done with PMMA bone cements 
showed equivalent or superior bioactive properties o f these fabricated scaffolds.
There was a significant reduction in mechanical strengths o f the PLA constructs 
due to addition o f bioactive compounds. Increasing the strengths o f  the constructs using 
nanoparticle technology or by using other additive polymers should be further 
investigated. Drug elution data showed a burst release o f  bioactive compounds for the 
first couple o f hours and then a steady release for 144 hours. Furthermore, by regulating 
the 3D printing parameters such as infill ratio and resolution, external surface area and
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hollowness o f  the constructs vary and thus increase or decrease the amount o f drug 
elution.
Finally, novel techniques were engineered to 3D scan and print custom constructs 
using bioactive filaments. These techniques show the potential o f 3D printing to create 
personalized medicines with targeted drug delivery.
CHAPTER 5
3D PRINTING HORMONES LOADED BIODEGRADABLE
CONSTRUCTS
5.1 Introduction
Osteoporosis is a critical bone health issue with devastating effects, especially for 
the aging population. Estrogen deficiency causes postmenopausal women to be at high 
risk o f  developing osteoporosis and subsequent bone fractures [120]. Estrogen is a crucial 
hormone in the pathogenesis o f osteoporosis, although the exact mechanism by which 
estrogen deficiency causing bone-mineral loss is not clearly understood [121, 122], Some 
studies have focused on the role o f estrogens in down-regulating the proinflammatory 
cytokines (IL-1, IL-6, TN F-a, PGE2 and other macrophage colony-stimulating factors) 
that aids in osteoclast functions and increases the bone resorption [123, 124]. Other 
studies have found that estradiol prevents the activation o f  caspase-3 enzyme, which is a 
crucial initiating factor for apoptosis o f  osteoblast cells [125, 126], Cenci et al. reported 
an increased bone loss/bone resorption in ovariectomized (OVX) mice, mediated by 
TN F-a [127]. These authors also showed that administration o f estrogen hormones 
prevented ovariectomy-induced bone loss.
Flormonal Replacement Therapy (HRT) with estrogen is the most common and 
effective FDA approved pharmacotherapy used to treat postmenopausal osteoporosis 
[125], Estrogens are available in various formulations and are administered via different
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routes such as intramuscular, subcutaneous, percutaneous, transdermal, vaginal, and oral. 
Depending on the patient’s profile and requirement, HRT is administered either as short­
term (2-4 years) or in long-term (usually more than 5 years) therapy. HRT implants are 
usually in the shape o f a small pellet or apple pips, made by fusing pure crystals o f 
hormones, and they are available in doses o f 50 mg -100 mg. These pellets are 
administered subcutaneously (under the fat lining o f the skin) to provide a steady release 
o f drug for a long period o f time [125, 128], Thigh, upper leg or lower abdomen are the 
common locations for implantation. In some cases, continuous administration o f  estrogen 
alone may cause uterus hyperplasia [129], To prevent this, a combination therapy o f 
estrogen and progesterone is prescribed.
In addition to osteoporosis, estrogen along with progesterone can cure vasomotor 
symptoms such as hot flashes, night sweats, dyspareunia and atrophic vaginitis. HRT is 
also used for a woman who has undergone hysterectomy (surgery where w om an’s uterus 
is removed) and for contraceptive effects. Intrauterine devices (IUDs) are considered to 
be excellent long-term birth control implants because o f their safe, effective, and easy to 
use properties [130], These are small T-shaped devices, as shown in Figure 5-1, made o f 
flexible plastic and are placed directly into the uterus, releasing small amounts o f 
hormones (estrogen and/or progesterone) for up to 12 years. These devices work by 
impairing sperm functions and preventing the fertilization o f egg.
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Uterus
Figure 5-1: IUD positioned in the uterus [131].
Anatomically, the uterus is positioned in the pelvic region with various muscle 
tissues and ligaments. Age, pregnancy, or estrogen deficiency cause these muscles to 
weaken in some women, and the uterus drops into the vaginal canal causing a prolapsed 
uterus. Pessaries are medical devices used to treat these pelvic organ prolapses by 
providing structural support to the uterus, vagina, bladder, rectum and deliver female sex 
hormones locally [132]. These devices are made in different sizes and shapes as shown in 
Figure 5-2. A physician decides the best fit o f  the pessary to the patient by a trial and 
error testing procedure [133]. Locally released estrogen could strengthen the pelvic floor 




Figure 5-2: Pessaries o f different shapes and sizes [135],
Currently available HRT implants are bulk manufactured with fixed doses, 
whereas every individual is unique and needs varied amounts o f hormones.
Commercially available HRTs do not account for the differences between individuals. 3D 
printing technology has simplified the generation o f customized medications for patients. 
The advantage o f customizing HRT is that it can be modeled specifically to fit the 
individual’s body and hormone level. In this part o f  the research, methods to fabricate 
customized hormonal implants will be discussed. These printed constructs will be tested 
for external morphology, hormonal elution profiles and therapeutic efficacy.
The Polycaprolactone (PCL) pellets used for filament extrusion were purchased 
from Sigma Aldrich (St. Louis, MO). Estrogen hormone El (SLE 1048) was purchased 
from ScienceLab.com, Inc. (Houston, TX). E2 (CAS 57-63-6) and E3 (CAS 50-27-1)
5.2 Materials
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were obtained from U.S. Pharmacopeia (Rockville, MD). Cell culture plates and other lab 
plastics were purchased from MidSci, St. Louis, MO. Rosewell Park Memorial Institute 
Medium (RPMI), Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum 
(FBS), and penicillin-streptomycin-amphotericin (PSA) antibiotics were obtained from 
Life Technologies, Carlsbad, CA. Estrogen receptor luciferase reporter T47D stable cell 
line (S1-0002-NP) was purchased from Signosis, Inc. (Santa Clara, CA). KJLC 705 
silicone oil used for coating the beads prior to extrusion was purchased from Kurt J. 
Lesker Company (Jefferson Hills, PA). The 3D printing equipment consists o f an 
ExtrusionBot extruder purchased from ExtrusionBot, LLC (Pheonix, AZ) and a 
MakerBot Replicator 5th Generation Desktop 3D printer (Brooklyn, NY). The nanodrop 
spectrophotometer was from Thermo Scientific (W ilmington, DE). The Solidworks 2015 
student edition 3D CAD program Dassault Systemes (Waltham, MA) and Blender 
(Amsterdam, NL) were used for modeling. ELISA kits for E2 and E3 were purchased 
from Enzo Life Sciences (Farmingdale, NY). To analyze ELISA assays, a SpectraMax 
M2e Multimode mircroplate reader purchased from Molecular Devices (Sunnyvale, CA) 
was used. The SEM was a hitachi S-4800 (Schaumburg, IL).
The filament extrusion devices, 3D printers, modeling software were previously 
described in Chapter 4. New materials are described in detail below.
5.2.1 Bioplastics
PCL was used as a thermoplastic polymer for loading hormones due to its lower 
melting temperature. It has a glass transition temperature o f -60°C and melting point at 




Synthetic female sex hormones E l, E2 and E3 were used for this research. These 
hormones are commercially available in powdered form, have chemical structures similar 
to natural hormones and act by competitively attaching to the estrogen receptors in the 
body. They have high melting temperatures o f El (255°C), E2 (180°C), E3 (280°C) and 
are thermally stable [136],
5.2.3 Micro-plate Reader
A SpectraMax M2e multimode microplate reader from Molecular Devices was 
used to measure the absorbance values o f the ELISA kits. Like any other plate reader, 
this works on principles o f Beer-Lambert’s law. SoftMax Pro software was used to run 
this machine. It also has the ability to run standards and calculate the concentrations o f 
unknowns from the standard values. Figure 5-3 shows the image o f the microplate 
reader.
Figure 5-3: SpectraMax M2e multimode multiplate reader.
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5.2.4 ELISA Kits for Hormone Quantification
ELISA kits for E2 and E3 were ordered form Enzo Life Sciences, Farmingdale, 
NY. There are no current active suppliers for El-ELISA  kits. These kits were competitive 
immunoassays for quantitative determination o f hormonal concentrations in the samples. 
These kits use polyclonal antibodies to bind competitively to hormones present in the 
sample. After incubating at room temperature, excess reagents were removed, the 
substrate was added and the process was halted using stop solution. The optical density o f 
the substrate was measured using microplate reader, and from those readings, 
concentration o f hormones in the samples were calculated.
5.2.5 Estrogen Receptor Luciferase Reporter Cell Line
Estrogen receptors belong to the nuclear receptor family. They are wide spread 
and are responsible for varied physiological functions. Estrogen receptor luciferase 
reporter T47D stable cell lines were purchased from Signosis, Santa Clara, CA. In these 
cell lines, when estrogen or similar stimulants attach to the estrogen receptors in the 
nucleus, dimerization o f these receptors takes place. These dimerized receptors attach to 
specific elements, located at the promoter site o f genes, known as Estrogen Response 
Elements (EREs). Upon attachment with these EREs, genes get activated and start 
expressing. These particular cell lines express luciferase on estrogen stimulation and thus 
provide a sensitive and responsive in vitro system to detect estrogen activity.
5.3 Fabricating Hormone Loaded Scaffolds
For filament extrusion and 3D printing, methods mentioned in Chapter 4, Sections
4.3.1 and 4.3.2 were followed. PCL thermoplastic was used for loading hormones due to 
its low melting temperatures and excellent biodegradable and biocompatibility properties.
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5.3.1 Extruding Hormone Loaded Filaments
PCL pellets were coated with calculated amounts o f hormones and extruded using
ExtrusionBot filament extruder in similar manner to PLA. Each 20 gm batches o f E l, E2 
and E3 were extruded at 90-100°C. Filaments extruded were more flexible when 
compared to PLA. Unlike PLA, to maintain the filament diameter o f 1.75 mm, manual 
regulation o f temperatures between 90°C tol00°C  were needed.
5.3.2 Optimizing 3D Printing Parameters
These extruded filaments were used in MakerBot 1st generation desktop 3D 
printer to print constructs. All E l, E2 and E3 constructs were printed at 110°C at a 
printer-head speed o f  10 mm/s. A constant filament-feed rate o f 23 mm/s was maintained 
throughout the printing process.
5.3.3 Scaffold Design and Fabrication
All 3D models such as lUDs and pessaries were designed using Solidworks 2015 
CAD designing software. Discs o f 5 x 1 mm dimensions were printed for drug elution 
testing and in vitro cell cultures. lUDs and pessaries o f different dimensions and shapes 
were also printed using the extruded filaments.
5.4 Scaffold Characterization
The 3D printed hormonal scaffolds were subjected to physical and bioactive 
testing. Surface morphology o f the constructs were studied using SEM, ELISA kits were 
used to study hormonal release from scaffolds and Luciferase assay was conducted to test 
the bioactivity o f  the hormonal discs.
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5.4.1 Morphology
Extruded filaments and printed discs o f different hormones were subjected to 
SEM using S4800 Field Emission SEM, HITACHI (Schaumburg, IL) at different 
magnifications. The surfaces o f  the constructs were nano-coated with the gold particles 
before imaging to make them conductive.
5.4.2 Hormone Elution Profiles
To calculate the amount o f hormone eluting from the constructs, an elution study 
was conducted. Saline was used for sample collection. Samples from E2 and E3 were 
collected at periodic intervals for a week. These collected samples were analyzed using 
respective ELISA kits. From the pilot studies we could determine that the concentration 
o f  E2 eluting from the scaffolds was over the maximum detection level and all the 
reading were near saturation. A ten-fold dilution o f the E2 samples and ELISA was 
performed. E3 samples had absorbance values within the ELISA detection range and 
were not diluted. The SpectraMax M2e multimode microplate reader was used to read the 
96 well plates absorbance values. From the absorbance values o f standards, the four 
parameter logistic (4PL) nonlinear regression model was drawn and concentrations o f 
unknown samples were back calculated. For all the assays, the absorbance values at 405 
nm were measured and recorded. The manufacturer’s protocol followed for this assay is 
mentioned in Appendix B.
5.4.3 Estrogen Receptor Luciferase Cell Culture
This study was conducted to test the hormonal activity in the 3D printed scaffolds. 
Plain PCL pellets, saline and different concentrations o f E2 were used as controls. 
Extruded filaments and 3D printed discs were used as unknowns. Before these scaffolds
were seeded, 90% confluent cells were detached from the culture tubes and suspended 
into RPMI medium. Each well was filled with 10 pi o f  suspension and incubated for 24 
hours for attachment. Scaffolds were added to these wells and incubated for another 16 
hours. Lysis buffer was added to each well and incubated for two minutes. In a new 96 
well plate, 20 pi o f  this lysate was transferred and 100 pi o f  luciferase substrate is added. 
Optical density o f each well is immediately read using a luminometer. The 
manufacturer’s protocol followed for this assay is described in Appendix B.
5.5 Statistical Analysis
For the ELISA assay, three samples o f each batch was tested and averaged for 
reproducibility. Standard deviation o f the means was calculated and mentioned in the 
elution profile graphs as error bars. For the in-vitro study, measurements from five wells 
o f each group were averaged. A one-way ANOVA was conducted to analyze the 
significant difference between the means among the groups. The standard deviation o f 
the mean was calculated and represented as error bars in the graphs.
5.6 Results and Discussion
PCL pellets were successfully coated with E l, E2 and E3 hormones. Each 20 gm 
batches o f  1.75 mm diameter filaments were extruded and required constructs were 
successfully printed. Figure 5-4 shows images o f  PCL constructs printed with and 
without hormones using Makerbot 3D printer. Constructs containing a combination o f 
hormones can be printed using this technique. Figure 5-4 D shows a donut shaped 






Figure 5-4: 3D printed constructs A) Control donut shaped pessary, B) Control 
gellhom shaped pessary, C) Control IUD, D) Pessary printed combinations o f filaments 
(red- PLA and white- PCL-E2), E) PCL-E1 IUD, and F) PCL-E2 IUD.
5.6.1 Scanning Electron Microscopy (SEM)
SEM was used to study the surface morphology o f the coated pellets, filaments 
and printed discs. Figure 5-5 shows the images o f estrogen hormones E l, E2, and E3.
Figure 5-5: SEM images o f  A) E l, B) E2, C) E3.
All these hormones contain irregular shaped particles o f varied sizes. The 
estimated largest size o f these particles was around 5 pm. Filaments extruded from 
ExtrusionBot were cylindrical in shape and had a smooth external surface. The image in 
Figure 5-6 show hormone loaded PCL filaments extruded using ExtrusionBot filament 
extruder.
2.00 mm
Figure 5-6: SEM images o f  A) E l , B) E2, C) E3.
These filaments were used in Makerbot 3D printer to print discs o f 5 mm x  1 mm 
dimensions. Images in Figure 5-7 A-C shows 3D printed discs used for ELISA and cell 
culture. On further magnification, hormone particles were seen on the surfaces o f these 
discs. Images in Figure 5-7 D, E and F shows E l, E2, and E3 particles on the surfaces o f 
the discs at 100X magnification.
Figure 5-7: SEM images o f (A,D) PCL-FJ Disc, (B,E) PCL-E2 Disc, (C,F) PCL-E3 
Disc.
5.6.2 Quantification through ELISA
Preliminary studies showed the release o f hormones were in nanograms 
concentration. A ten-fold dilution o f  the samples were done to meet the ELISA kits 
detection range. Samples were collected, one for each day. To calculate the 
concentrations o f E2 and E3 released from the constructs, standard graphs shown in 
Figure A-5 and Figure A-6 of the Appendix A were used, respectively. Table 5-1 shows 
the concentration o f  hormone E2 released from 3D printed PCL-E2 discs at a given time 
period. For the first two days, 35% o f total hormone was released from the scaffolds. The 
release o f  the hormones from the 3D printed constructs can be regulated by altering infill 
ratio. Using dual head 3D printer, layers o f the constructs can be printed in alternating 
hormone loaded and unloaded pattern.
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Table 5-1: Concentration o f E2 hormone released from PCL-E2 discs for individual 
days, (mean ± SD, n = 3)








The graph in Figure 5-8 shows the concentration o f hormone E2 released over a 
period o f  one week. A total o f 215 ng/ml o f cumulative concentration o f E2 hormone was 
released at the end o f  day seven. Even after seven days, small quantities o f hormone 



















Figure 5-8: Cumulative concentration o f  E2 released from PCL-E2 discs (mean ± SD, 
n = 3).
The resolution o f  the 3D printed constructs can be changed by altering the layer 
height o f the filament deposited. With decrease in layer height o f the filament, surface 
area o f  the construct increases and in turn increases the hormonal release. All the 
hormone loaded discs were 3D printed at 300 pm resolution. T able 5-2 shows the 
concentration o f  hormone E3 released per day from 3D printed discs. Preliminary tests 
showed the release o f  E3 hormones from the constructs were within the detectable range 
o f the ELISA kits. So no further dilution o f  these samples were done. For the first two 
days, 46% o f total hormone was released from the scaffolds. On day seven, 1.3 ng/ml 
hormone was released.
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Table 5-2: Concentration o f  E3 hormone released from PCL-E3 discs for individual 
days.








Figure 5-9 shows the cumulative concentration o f  E3 released from PCL 
scaffolds for a period o f seven days. All samples were tested in multiples o f  three. Error 
bars in the graph are standard deviations. A standard graph plotted from the known 
concentration was used to yield four parameter logistic curve as shown in Figure A-6. E3 
release increased during the first four days, after which hormonal elution was steady and 
extended. A total o f 118 ng/ml (cumulative concentration) o f E3 hormone was released 
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Figure 5-9: Cumulative concentration o f E3 released from PCL-E3 discs (mean ± SD, 
n = 3).
5.6.3 In vitro Assay
Figure 5-10 shows the Relative Light Unit (RLU) values o f luciferase activity in 
response to estrogen stimuli. Five wells o f each group were tested and ANOVA analysis 
was conducted. The difference between the control cells and control PCL pellets was not 
statistically significant, indicating that the PCL pellets are biocompatible and do not 
promote any estrogen induced pathways. The group containing E2 showed a robust 
increase in RLU values when compared to groups without inducing agent, indicating the 
presence o f bioactive compounds in the fabricated constructs. Wells containing 100 
pg/ml concentration o f  E2 showed a total o f 84.6% more luciferase activity. Luciferase 
activity for extruded filaments (1 cm length) and 3D printed discs (5 mm X 1mm) 
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Figure 5-10: RLU values o f Estrogen receptor luciferase reporter cells incubated with 
different groups o f  E2 scaffolds (mean ± SD, n = 5).
5.7 Conclusions
Fused deposition modeling was used for the first time to fabricate hormone loaded 
biodegradable implant materials. Female sex hormones (E l, E2, and E3) were coated on 
to PCL pellets and filaments o f required dimensions were successfully extruded. With 
these bioactive enhanced filaments, constructs o f required shapes such as IUD, different 
sizes and shapes o f  pessaries were 3D printed using MakerBot 3D printer.
SEM images showed extruded filaments were smooth and cylindrical in nature. 
The study o f release kinetics using ELISA assay showed that the hormones E2 and E3 
were released at a steady rate from the scaffolds over an extended period.
In vitro assays conducted on estrogen receptor luciferase reporter cell lines show 
that scaffolds fabricated were biocompatible. Groups enhanced with hormones showed 
robust luciferase activity, indicating the presence o f bioactive inducing substance (E2) in 
the scaffolds.
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The ability to 3D print estrogen-loaded biodegradable implants holds huge 
potential in personalized medicine. Using these methods, IUDs and pessaries can be 
tailored to a patient’s specific needs in aspects o f the unique anatomy o f the individual, 
hormone dosage and period o f hormone therapy.
CHAPTER 6 
CONCLUSIONS AND FUTURE WORK
6.1 Conclusions
Novel CPCs enhanced with doped HNTs were successfully formulated and 
evaluated. The addition o f HNTs up to 5%wt increased the compressive and flexural 
strengths o f the scaffolds. A further increase in the concentration o f HNTs did not yield 
higher mechanical strength statistically. SEM showed an increase in surface roughness 
upon addition o f HNTs to the CPC composition. Drug-loaded HNTs added in the CPC 
scaffolds showed an initial outburst o f the bioactive compounds and then an extended 
release up to a week. CPC discs loaded with different concentrations o f HNTs showed 
clear demarcating zone o f inhibitions for E.coli and P. aureus.
This study demonstrated the novel methods to fabricate 3D constructs with 
bioactive properties using a desktop 3D printer. Filaments o f required bioactive agent 
(antibiotic, chemotherapeutic or hormone) were successfully prepared using 
ExtrusionBot filament extruder. This work highlights the advantages and difficulties 
associated with this novel fabricating technique. SEM was used to characterize the 
morphology o f  the extruded filament and 3D printed scaffolds. Traces o f  bioactive 
materials were observed on the surface o f the scaffolds via SEM. Scaffolds with different 
mechanical strengths were constructed using different infill ratios. Compression and
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flexural strengths increased with an increased infill ratio. Drug release profiles from the 
3D printed PLA and PCL scaffolds showed initial outburst and then extended steady 
release for a week. XTT assays on a human osteoblast cell line confirmed 
biocompatibility o f these fabricated constructs.
E.coli bacterial cultures demonstrated the anti-infective properties o f  the GS 
loaded PLA scaffolds. XTT assay conducted on osteosarcoma cell lines confirmed 
chemotherapeutic ability o f MTX loaded PLA constructs. Similarly, luciferase assay 
conducted on estrogen receptor luciferase reporter cell line showed estrogen hormone 
activity among E2 loaded PCL scaffolds.
Antibiotic- and chemotherapeutic-loaded beads and catheters were successfully 
printed, and their bioactivity on bacterial and osteosarcoma cell cultures, respectively, 
was confirmed. lUDs and Pessaries o f different shapes and dimensions were printed 
using estrogen loaded PCL filaments.
Critical defects were made on a cow ’s femur bone using standard drilling 
machine. Defects were 3D scanned, processed and 3D printed successfully using custom 
extruded drug loaded filaments. Additionally, this study demonstrated strategies for 
adopting 3D printing technology to fabricate scaffolds for tissue regeneration. The 3D 
printed constructs were optimized and used as supporting materials to generate live 
vascular prostheses. The dimensions o f  these vessels can be customized in terms o f its 
length, diameter and wall thickness by varying dimensions o f the scaffolds. The same 
technique can be used to fabricate complex or branched vascular grafts.
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6.2 Future W ork
Novel 3D printing machines using additive manufacturing techniques allows the 
design o f the patient’s specific prosthetic implants to suit individual anatomy, improve 
functionality and reduce implant failures. However, much work and research remains to 
be accomplished. Among a large variety o f biopolymers, only PLA and PCL were used in 
this study. This study can be conducted using other biodegradable polymers such as PLG 
(poly glycolides) and PLGA (poly (lactic-co-glycolic acid)). Additionally, in vivo animal 
studies can be done. The following are some o f the ongoing projects on 3D printing.
6.2.1 Surgical Mesh
Surgical mesh is a medical device used to provide mechanical support to damaged 
or weakened tissues. These devices are used in procedures such as pelvic organ prolapse, 
inguinal hernia, and others. These devices are intended to stay at the site, provide support 
to the tissues and gradually degrade allowing the formation o f  neotissue at the site.
Depending upon the place o f  the implantation, various meshes with different 
weights, filament size, pore size and weaving structures are used. A 3D printer can be 
used to print biodegradable, and biocompatible meshes can be printed with customizable 
parameters and inculcating bioactive nature. F igure 6-1 shows the 3D printed PLA 
meshes and zone o f inhibition o f E.coli by 1% wt GS-PLA mesh.
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Figure 6-1: A) 3D printed Plain PLA surgical mesh, B) zone o f inhibition o f l% wt 
GS-PLA on E. coli bacterial plate.
6.2.2 Live Vascular Grafts
Vascular prosthesis or grafts are medical devices used to replace or bypass 
damaged or diseased blood vessels. Biological grafts do not cause immunological 
responses and are preferred over synthetic prosthesis. 3D printing can be used to fabricate 
vascular scaffolds with a wide variety o f shapes and dimensions. Treating these scaffolds 
chemically can make their surface suitable for cell attachment and growth. Figure 6-2 
shows the process o f fabricating a live vascular graft.
Figure 6-2: A) CAD model o f vascular stent, B) 3D printed stent using PVA,
C) Seeding cells on to the scaffold, D-E) Cells growing on the stent.
Scaffolds for vascular grafts were 3D printed from a PVA thermoplastic. These 
scaffolds were sterilized, and the surfaces were chemically treated for cell attachment. 
Placental stem cells in a collagen matrix were seeded on to the scaffolds and incubated in 
a cell culture medium. Images in F igure 6-2 D) and E) show the stem cell layer growing 
around the vascular scaffold.
APPENDIX A
STANDARD GRAPHS FOR DRUG ELUTION PROFILES
Standard Graphs for GS and NS Used in CPC Evaluation 
Figure A -l shows the standard graph plotted with absorbance values o f  known 
concentration o f GS. From the graph linear equation was derived and all the unknown 
concentration o f the samples are back calculated from their absorbance values. Similarly, 
Figure A-2 was used to calculate unknown values NS from CPC-NS.
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Figure A-2: Standard graph used for calculating NS concentration for CPC samples.
Standard Graphs for GS and MTX Used in PLA Evaluation
The graph in Figure A-3 was plotted with known values o f GS concentrations 
against their absorbance values. Best fit equation was derived from it and unknown 
concentrations are back-calculated using the equation.
126
2
y = 0.4128ln(x) + 1 .9752..*  1-8
1.6
1.4
y  1 .2
i






Concentration (m g/m l)
Figure A-3: Standard graph used for calculating GS concentration from 3D printed 
constructs.
Similarly, Figure A-4 was used to calculate the best fit equation from the 
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Figure A-4: Standard graph used for calculating MTX concentration from PLA-MTX.
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Standard Graphs for E2 and E3 ELISA 
Graphs in Figure A-5 and Figure A-6 are standard graphs used to calculate the 
unknown concentrations o f hormones E2 and E3 respectively. These graphs were 
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Figure A-6: Standard graph used for calculating E3 concentration from PCL-E3 discs.
APPENDIX B
PROTOCOLS FOR CELL CULTURE TECHNIQUES
XTT Assay Protocol for Osteoblast and Osteosarcoma Cells
A 96 well plate was used for this assay. Five wells were set as blank with just 
medium and without cells. This assay was performed on Days 3,7 and 14.
• Well plates were taken out o f  the incubator and aspirated completely.
•  Each well was added with 80 pi o f PBS and 20 pi o f XTT stock solution.
• These plates were incubated for 2 hours.
• Absorbance values from wells were read at 450 nm using multiplate reader.
ELISA Protocol for E2 and E3 Hormones
All reagents required for the assay such as assay buffer, E2 standards and 
conjugates were supplied by the manufacturer and were prepared according to the 
manufacturers protocol.
• Non-specific binding (NSB) wells were filled with 150 pi o f assay buffer and 100 
pi o f  assay buffer into the remaining wells.
•  Each 100 pi o f standard known concentrations o f the samples were added into the 
specified wells.
• All wells, except for blank wells, were added with 50 pi o f blue conjugate.
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•  Immediately, all wells except for blanks and NSB wells, were added with 50 pi o f 
yellow antibody.
•  This plate was sealed and kept on a rocker for two hours at 500 rpm.
•  All the contents o f the wells were emptied and washed 3-4 times using wash
buffer.
•  All wells were then added with 200 pi o f  substrate solution.
•  These plate was then incubated for one hour without shaking.
•  All wells were then added with 50 pi o f  stop solution.
• Optical densities o f the wells were read immediately at 405 nm.
Luciferase Assay Protocol for Estrogen Receptor Cells
Estrogen receptor luciferase reporter T47D stable cell line was used to perform 
the luciferase assay. As soon as cells were shipped, entire contents o f the vial were 
thawed and transferred into a culture dish using RPMI medium. On 90% confluent 
growth, cells were split and used for assay.
• The cells were seeded on a 96 well plate for overnight with DMEM medium 
containing 10% FBS and incubated.
• Inducing agents or test samples were added to each well directly and incubated 
for 16 hours.
• Media was aspirated and 100 pi o f PBS was added to each well.
• After 5 minutes, media was aspirated again and 50 pi o f  lysis buffer was added to
each well.
• Cells were incubated in lysis buffer for 20 minutes at room temperature.
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• To ensure complete lysis o f  the cells, plate was rock cultured for 5 minutes at 500 
rpm.
• One freeze-thaw cycle at -80°C and room temperature was performed to ensure 
complete lysis o f the cells.
• A new 96 well plate was taken and 20 pi o f lysate is transferred from each well.
• To this new plate, 100 pi o f  luciferase substrate was added and gently pipetted up 
and down for thorough mixing.
• Plate was read under luminometer immediately.
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